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iRésumé
La dysplasie broncho-pulmonaire (DBP), caractérisée par un défaut de l’alvéolarisation, est 
une complication pathologique associée à un stress oxydant chez le nouveau-né prématuré. 
La DBP est présente chez près de 50 % des nouveau-nés de moins de 29 semaines de 
gestation. La nutrition parentérale (NP) que ces nouveau-nés reçoivent pour cause 
d’immaturité gastro-intestinale est une source importante de stress oxydant. En effet, leur 
NP est contaminée par des peroxydes, dont l’ascorbylperoxyde qui est une forme 
peroxydée du déshydroascorbate. La génération des peroxydes est catalysée par la lumière 
ambiante. La photoprotection de la NP, quoique difficile d’application en clinique, est 
associée à une diminution de l’incidence de la DBP chez les enfants prématurés. Chez 
l’animal nouveau-né, la photoprotection de la NP est associée à un meilleur développement 
alvéolaire. Ainsi, nous émettons l’hypothèse que l’ascorbylperoxide infusé avec la NP 
cause la perte d’alvéoles suite à une apoptose exagérée induite par l’oxydation du potentiel 
redox du glutathion. Cette oxydation du potentiel redox serait occasionnée par l’inhibition 
de la transformation hépatique de la méthionine en cystéine, menant à une diminution de la 
synthèse de glutathion au foie et dans les tissus tels que les poumons. La confirmation de 
cette hypothèse suggérera qu’un ajout de glutathion dans la NP permettra une meilleure 
détoxification de l’ascorbylperoxide par l’action de la glutathion peroxydase, et préviendra 
l’oxydation du potentiel redox et ainsi, la perte d'alvéoles par apoptose.
Objectifs : Le but de mon projet de recherche est de comprendre les mécanismes 
biochimiques liant la NP et le développement de la DBP chez le nouveau-né prématuré et 
de proposer une alternative nutritionnelle prévenant le développement de cette 
complication fréquemment observée dans cette population. Les objectifs spécifiques sont :
1) d’évaluer l’impact, au poumon, de l’infusion de l’ascorbylperoxyde sur l’axe 
métabolique potentiel redox du glutathion - apoptose - le développement alvéolaire; 2) 
d’étudier l’impact de l’ascorbylperoxyde et du potentiel redox sur l’activité hépatique de la 
méthionine adénosyltransférase (MAT), première enzyme de la cascade métabolique 
transformant la méthionine en cystéine; et 3) de tenter de prévenir l’impact négatif de la NP 
ou de l’infusion d’ascorbylperoxyde sur le poumon en améliorant le statut en glutathion.
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Méthodes: Par un cathéter fixé dans la jugulaire, des cochons d’Inde de trois jours de vie 
(n = 8 par groupe) ont reçu en continu durant 4 jours une NP ou une solution de base 
(dextrose + NaCl) enrichie des différentes molécules à l’essai. Le premier objectif a été 
DWWHLQWHQHQULFKLVVDQWODVROXWLRQGHEDVHHQDVFRUE\OSHUR[\GHjHWȝ0&HV
VROXWLRQVFRQWHQDLHQWRXQRQȝ0+2O2 pour se rapprocher des conditions cliniques. Le 
second objectif a été atteint en investiguant les mécanismes d’inhibition de la MAT dans 
des animaux infusés ou non avec des solutions contenant la solution de base, des 
peroxydes, du glutathion et la NP (dextrose + acides aminés + multivitamines + lipides). Le
troisième objectif a été atteint en ajoutant ou non à une solution d’ascorbylperoxide ou à la 
13ȝ0GHJOXWDWKLRQ*66*DILQG¶REWHQLUXQHFRQFHQWUDWLRQSODVPDWLTXHQRUPDOHGH
glutathion. Après 4 jours, les poumons étaient prélevés et traités pour la détermination de 
GSH et GSSG par électrophorèse capillaire, le potentiel redox était calculé selon l'équation 
de Nernst et le niveau de caspase-3 actif (marqueur d’apoptose) par Western blot et l’index 
d’alvéolarisation quantifié par le nombre d’interceptes entre des structures histologiques et 
une droite calibrée. Les données étaient comparées par ANOVA, les effets étaient 
considérés comme significatifs si le p était inférieur à 0,05.
Résultats: L’infusion de l’ascorbylperoxyde, indépendamment du H2O2, a induit une 
hypoalvéolarisation, une activation de la caspase-3 et une oxydation du potentiel redox de 
manière dose-dépendante. Ces effets ont été empêchés par l’ajout de GSSG à la NP ou à la 
solution d’ascorbylperoxyde (180 PM). L’ascorbylperoxyde et le H2O2 ont inhibé l’activité 
de MAT tandis qu’elle était linéairement modulée par la valeur du potentiel redox 
hépatique. 
Conclusion : Nos résultats suggèrent que l’ascorbylperoxyde est l’agent actif de la NP 
conduisant au développement de la DBP. Ainsi la correction des bas niveaux de glutathion 
induits par les peroxydes de la NP favorise la détoxification des peroxydes et la correction 
du potentiel redox pulmonaire ; ce qui a protégé les poumons des effets délétères de la NP 
en outrepassant l’inhibition de la MAT hépatique. Nos résultats sont d'une grande 
importance car ils donnent de l'espoir pour une prévention possible de la DBP.
Mots-clés : dysplasie broncho-pulmonaire, nouveau-nés prématurés, stress oxydant, 
alvéolarisation, nutrition parentérale, ascorbylperoxyde.
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Abstract
Bronchopulmonary dysplasia (BPD) is a major complication of preterm newborns,
affecting nearly 50% of infants born before 29 weeks of gestation. BPD is characterized by 
an arrest in alveolar development. The onset of BPD is related to oxidative stress. Research 
has shown that parenteral nutrition (PN), which is given to preterm newborns to bypass an 
immature gastrointestinal system, is a major source of oxidative stress. Indeed, PN is 
contaminated with peroxides, including ascorbylperoxide, an oxidized form of 
dehydroascorbic acid. Ambient light is a catalyst for the generation of peroxides. Photo-
protection of PN, although difficult to apply in the clinical situation, is associated with a 
lower incidence of BPD in premature infants and with better alveolar outcomes in animal 
models of neonatal PN. We hypothesized that the ascorbylperoxide in PN disrupts alveolar 
development. The main mechanism of action is an inhibition of the transformation of 
methionine into cysteine in the liver, leading to a lower glutathione synthesis in the liver as 
well as in peripheral tissues such as lung. Lower glutathione (GSH) concentrations favour a 
shift of redox potential to a more oxidized state and consequently, to exaggerated 
apoptosis. If our hypothesis is correct, the addition of glutathione to PN would help 
detoxify ascorbylperoxide through the action of glutathione peroxidase and prevent the 
deleterious impact of PN.
Objectives: The aims of my research project were to investigate the biochemical 
mechanisms linking PN to the development of BPD in premature newborns and to propose 
a nutritional alternative that would prevent the occurrence of this frequently observed 
complication. Specific objectives were: 1) to assess the effect of intravenously infused 
ascorbylperoxide on the metabolic axis redox potential of glutathione in the lung; 
specifically, apoptosis and the alveolarization index; 2) to study the impact of 
ascorbylperoxide and the redox potential on the activity of methionine adenosyltransferase
(MAT) in the liver; methionine adenosyltransferase is the first enzyme in the metabolic 
cascade from methionine to cysteine; and 3) to try to prevent the deleterious impact of PN 
or ascorbylperoxide infusions on the lung by improving glutathione status.
Methods: Through a catheter in the jugular vein, 3-day-old guinea pigs (n = 8 per group) 
received continuous infusions of PN or a simple solution (dextrose + NaCl) enriched with 
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different molecules for testing. The first objective was achieved by enriching the basic 
solution with ascorbylperoxide at concentrations of 0, 20, 60 and 180 PM. To mimic 
clinical conditions, these solutions contained, or not, 350 PM H2O2. The second objective 
was achieved by investigating the mechanisms of MAT inhibition in animals infused, or 
not, with solutions consisting of the basic solution, peroxides, glutathione, and PN 
(dextrose + amino acids + multivitamins + lipids). The third objective was achieved by 
adding, or not, 10 PM of glutathione (GSSG) to the ascorbylperoxide or PN solution until a 
normal plasma concentration of glutathione was obtained. After 4 days, the lungs were 
removed. GSH and GSSG levels in the lungs were determined by capillary electrophoresis. 
The redox potential was calculated using the Nernst equation. The activation and the 
concentration of active caspase-3 (marker of apoptosis) were determined by Western blot, 
and the alveolarization index quantified by the number of intercepts between histological 
structures and a calibrated straight line. Data were compared by ANOVA; effects were 
considered significant if p was less than 0.05.
Results: The infusion of ascorbylperoxide, independently of H2O2, induced 
hypoalveolarization, activation of caspase-3, and oxidation of the redox potential, in a 
dose-dependent manner. These effects were prevented by the addition of GSSG to the 
ascorbylperoxide (180 PM) or PN solutions. Ascorbylperoxide and H2O2 inhibited MAT 
activity in the liver. Hepatic MAT activity was linearly modulated by the value of the redox 
potential.
Conclusion: Our results suggest that ascorbylperoxide is the active ingredient in PN that 
leads to the development of BPD. Correcting the low glutathione levels induced by 
peroxides in PN solutions would promote the detoxification of peroxides and re-establish 
proper pulmonary redox potentials. Glutathione correction further protects the lungs from 
the deleterious effects of PN by bypassing hepatic MAT inhibition. This result is of great 
importance because it gives hope for the possible prevention of BPD.
Keywords: bronchopulmonary dysplasia, preterm newborns, oxidative stress, 
alveolarization, parenteral nutrition and ascorbylperoxide.
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11. Introduction
In Canada, the number of extremely SUHWHUPEDELHV 8 weeks’ gestation) is increasing 
(1% of births). The incidence of several complications associated with prematurity is high; 
for example, bronchopulmonary dysplasia (BPD).[1] BPD is characterized by an arrest in 
alveolar development that makes the newborn dependent on oxygen supplementation until 
at least 36 weeks’ postmenstrual age (PMA) . [2] In Canada, BPD affects one extremely 
premature infant (< 28 weeks’ gestation) out of two. Consequences of BPD are many; for 
instance, lung function impairment during childhood, chronic lung disease, and impairment 
of neurodevelopment. For a long time, it was thought that oxygen supplementation was the 
root cause of the oxidative stress that underlies the etiology of BPD. More recently, it has 
been suggested that the administration of parenteral nutrition (PN) to bypass the immature 
gastrointestinal track of these infants might play an important role in BPD development. 
Indeed, light exposure to PN induces the production of peroxides such as ascorbylperoxide 
and hydrogen peroxide (H2O2) and increases the risk of oxidative stress. These peroxides 
are suspected to have a deleterious effect on the lung and to induce BPD. The aims of this 
research are to understand the mechanistic processes linking PN to BPD development, in 
order to optimize nutritional support of preterm infants without exposing these vulnerable 
children to any additional burden.
To better understand the issues raised by PN, I will review the main considerations in the 
following sections: 1.1 prematurity, 1.2 nutritional requirements for premature infants and 
parenteral nutrition, 1.3 lung development, 1.4 apoptosis and lung development, 1.5 
bronchopulmonary dysplasia, 1.6 oxidative stress, and 1.7 premature antioxidant defense 
system. 
21.1 Prematurity 
According to the world health organization (WHO), preterm is defined as babies born alive 
before 37 weeks of pregnancy are completed. There are sub-categories of preterm birth, 
based on gestational age:  
Moderate to late preterm (32 to <37 weeks): infants born between 32 and 37 weeks of 
gestation. This category is the most likely to survive with supportive care.
Very preterm (28 to <32 weeks): infants born between 28 and 32 weeks of gestation. These 
babies need supportive care. 
 Extremely preterm (<28 weeks): infants born before 28 weeks of gestation. This is the 
category with the highest mortality rate. These very small babies, if they survive, may 
require extensive and expensive intensive care [3, 4]
There is another definition for premature infants based on birth weight, as shown in Table 
1. [5,6]
Table 1. Prematurity types based on birth weight. 
Birth weight Definition 
1500 to 2500 g Low birth weight
1000 to 1500 g Very low birth weight
to1000 g Extremely low birth weight
31.1.1 Incidence and cause of preterm birth
The preterm birth rate worldwide is about 11%, and about 15 million babies are born 
preterm each year. Of these preterm births, 84% occur between 32 - 36 weeks of
gestational age (GA), 10% occur at 28 to < 32 weeks GA and 5% occur at < 28 weeks GA 
[7]. In 2010–2011, the preterm birth rate in Canada was 7.9%. This rate has remained 
stable since 2006–2007 (8.1%). Preterm births increased in developed countries in 
association with the number of older women having babies and multiple pregnancies.[8]
However, in developing countries, preterm births increased due to high adolescent 
pregnancy rates as well as infections such as malaria. Preterm birth occurs primarily for 
three reasons: 1) through spontaneous delivery due to early labor or premature rupture of 
the placental membranes; 2) as an early delivery when the mother has health problems such 
as preeclampsia; or 3) through calculation error in due dates. [8] 
Events leading to preterm birth are not well understood. The etiology is deemed to be 
multifactorial. The risk factors for preterm deliveries are medical conditions of the mother 
(obesity, diabetes, hypertension, smoking, infection, maternal age), genetics, environmental 
exposure, socioeconomic factors and multiple birth [9]. Prematurity has a great impact on 
the child’s health, family and society. In fact, preterm birth is associated with highly costly 
intensive care services which would be challenging to deal with in poor countries.
The incidence of pathological complications associated with prematurity is inversely 
proportional to gestational age at birth; for example, BPD, a major complication of preterm 
birth, is characterized by reduced alveolar development requiring long-term respiratory 
support due to lung immaturity. [10, 11]
For this reason, BPD is considered a developmental disease with arrested lung 
development. In Section 1.4, I will describe the stages in lung development during 
4pregnancy and after birth. Further, I will show at which stages of lung development 
premature birth occurs. BPD is at the heart of my PhD work; see section 1.3.
1. 2 Nutritional requirements for premature infants 
During intrauterine growth, the fetus gets its nutrients from the mother. Unfortunately, 
preterm birth perturbs the delivery of these nutrients [12]. The inadequate nutrition during 
the early postnatal period is associated with an increased incidence of complications of 
preterm birth, such as abnormal neurodevelopment and chronic lung disease [13]. Early 
adequate nutrition in premature infants is therefore essential.
1.2.1 Goals of nutrition in premature infants
In utero, the fetus grows at a minimum rate of 15 g/kg/day. Thus the goal of nutritional 
supplementation in premature infants is to reach a postnatal growth rate similar to that of 
the normal fetus at the same gestational age. [14, 15] However, this weight gain in preterm 
infants is often hard to achieve due to higher energy expenditures in extrauterine life as 
compared to intrauterine life. The reasons for higher expenditures are related to the 
intensive care environment, medical consequences, and inadequate nutrition [15].
Very preterm and extremely low birth weight (ELBW) infants will therefore need more 
intensive nutritional support [16]. Indeed, about 97% of very low birth weight (VLBW) 
infants had poor growth at 36 PMA. The reason is that preterm infants are often not fed 
enough protein and energy to meet the requirements for a growth rate similar to that of a 
normal fetus [17]. This observation is supported by several recent and older studies that 
have shown that adequate nutritional support can prevent the protein [18, 19, 20] and 
carbohydrate shortage and improve the growth of preterm infants. [21]
In order to achieve neonatal growth rates similar to those of the normal fetus, early PN is 
recommended soon after birth [22]. Infants born before 28 weeks’ gestation, or VLBW 
5infants, required full PN. In premature infants, full enteral feedings are often delayed 
because of the medical problems associated with prematurity such as BPD, infections, 
necrotizing enterocolitis, and retinopathy of prematurity. In the first two weeks of birth, 
nutritional requirements of VLBW infants are frequently met by PN. PN provides balance 
in fluid homeostasis and electrolytes, avoids imbalance in macronutrients, and provides 
micronutrients and vitamins. [23]
Whereas previously this mode of nutrition for premature infants was often neglected, it is 
currently gaining in importance. The recommended PN includes: 1) sufficient calories for 
energy expenditure and infant growth; 2) carbohydrates to prevent hypoglycemia and 
proteins (essential amino acids) to meet nitrogen balance required for growth; 3) fatty acids 
to avoid essential fatty acid deficiency and prevent metabolic complications of glucose 
overfeeding; and 4) essential nutrients such as minerals, electrolytes, vitamins, and trace 
elements necessary for growth. [24]
6Table 2. Protein, carbohydrates and lipid requirements in preterm infants on parenteral 
nutrition adapted from Velaphi et al.
Energy 110-120 kcal/kg/day
Protein 
< 30 weeks
30-36 weeks
> 36 weeks
3.5-4.0 mg/kg/day
2.5-3.5 mg/kg/day 
1.5-2.5 mg/kg/day
Carbohydrates (glucose) 6-8 mg/kg/day
Lipids 2.5-3.5 g/kg/day
1.2.2 Energy requirements 
Preterm infants have low energy reserves because they were born before they could 
accumulate fat and glycogen reserves [15]. Energy requirements depend on the stage of 
development and gestational age; for instance, the energy needs for infants born at 24 
weeks’ GA are higher than for those born at 38 weeks’ GA. The recommended daily 
energy intake of healthy premature infants is 110-120 kcal/kg/day to allow for growth rates 
similar to those in utero [15].
1.2.3 Carbohydrates 
Carbohydrates are the main energy source for premature infants receiving PN in the form 
of glucose. The rate of glucose synthesis is different for preterm and term infants: 6-8
mg/kg/minute and 3-5 mg/kg/minute, respectively [15]. Because an adequate amount of 
7glucose is critical for growth and neurodevelopment, glucose levels are monitored at 
initiation of and during PN in order to maintain serum glucose concentrations and avoid 
hypo- and hyperglycemia. [25, 15]
1.2.4 Lipid requirements
Lipids are considered an important source of energy in PN for premature infants. 
Additionally, lipids provide essential fatty acids which are required, among others, for 
brain and visual development [26]. Parenteral lipid emulsions also facilitate the delivery of 
lipid-soluble vitamins. A lipid infusion rate of 3 g/kg/day provides the necessary essential 
fatty acids and energy levels [27].
1.2.5 Protein requirements 
Proteins are essential for premature growth and development. Several clinical studies have 
reported that higher protein and energy intakes have markedly increased the growth, head 
circumference, brain size, and cognitive function of premature infants [28]. The protein 
recommendation for infants depends on GA at birth. As shown in Table 2, intravenous 
amino acids must be administered to provide protein of 3.5–4.0 g/kg/day for infants < 30 
weeks’ GA at birth; 2.5-3.5 g/kg/day for infants 30 to 36 weeks and 1.5-2.5 g/kg/day for 
infants > 36 weeks of GA at birth. [29] 
1.2.6 Electrolytes, minerals, and vitamins
During the first postnatal week, electrolyte needs are relatively low because of free water 
diuresis. [15] However, during the growing phase, sodium requirements are increased. 
Calcium, magnesium and phosphorus are necessary for tissue structure and function. 
During the last trimester of pregnancy, calcium is actively transferred from mother to fetus 
at the rate of 120-150 mg/kg of fetal weight per day [15]. Thus, preterm infants born before 
8the last trimester are at risk of low bone mass and bone disease. Calcium and phosphorus in 
PN is a challenge because of their limited solubility. [30] 
Water-soluble and lipid-soluble vitamins are low in the premature infant population. They 
should be infused as soon as PN is started. There are different types of multivitamin 
preparations in the world. However, in North America, only one multivitamin preparation 
is available that contains both water-soluble and lipid-soluble vitamins (Multi-12 from 
Sandoz, Boucherville, Qc, Canada). Elsewhere, e.g. in Europe, there are several 
multivitamin preparations with these two types of vitamins. In my doctoral work, we used 
the Multi-12 pediatric preparation. [15] 
Parenteral multivitamin preparations are very important for the nutritional needs of the 
infant; however, this mode of vitamin delivery has undesirable effects. See Section (1.7.6) 
on PN (or parenteral multivitamin preparation) as a major source of oxidative stress.
1.3 Lung
1.3.1 Normal structure of lung
The lungs are the primary organs responsible of respiration in humans and animals. The 
lungs are located in the central area of the thoracic cavity. The lungs are paired on either 
side of this central area. The right lung has three lobes, and the left lung has two lobes 
allowing a space for the heart. A lobe is further divided into lobules, and each lobule has a 
bronchiole serving many alveoli. The first structure allowing the air to entering the lung is 
the trachea. It is divided subsequently into two bronchi. The cartilaginous component of 
their wall maintains these ways open. Inside the bronchi, the epithelium is composed of 
pseudostratified columnar cells, which include basal cells, ciliated cells and goblets cells. 
These last one are responsible for mucus production.
9Bronchi are subsequently divided in bronchioles that are further divided into smaller 
bronchioles. This last one, also named terminal bronchiole, leads air to acini (primary 
lobule), a group of alveoli that constitutes the first component of gas exchange. At the 
junction of bronchioles and alveoli, the Clara cells, similarly to alveolar type II cells, are 
secretory cells contributing the lining layer of the lungs. In addition, they also act as stem 
cell for epithelial renewal. [31, 32]
Alveoli, at number about 300 million in lungs, are the main point of gas exchange. It is a 
hollow cavity that is surrounded by an epithelium. The gas exchange occurs, by diffusion, 
with the numerous blood capillaries surrounding the alveoli. [34]
The epithelium of alveoli contains three types of cell. Type I cell forms the structure of the 
alveoli. Type II cell produces the surfactant and acts as stem cell for alveolar epithelium. 
The type III cell (pulmonary alveolar macrophage) derived from blood monocyte, acts as 
scavenger (dust cell). [31, 33]
1.3.2 Lung development in infancy
Lung development is a process that involves interactions between epithelial and 
mesenchymal tissue starting at the fourth week of gestation and continuing after birth. [31] 
The embryonic stage (4-7 weeks of gestation) includes the first appearance of the lung. It is 
a critical period of cellular differentiation and branching morphogenesis, when gross 
changes in lung structure can occur. The pseudoglandular stage (7-16 weeks’ gestation) 
includes branching of the airways and blood vessels. Next, in the canalicular stage (16-26 
weeks’ gestation) there is further development of the blood supply to the peripheral 
mesenchyme. [32] The saccular phase includes differentiation of the respiratory airways 
and differentiation of future respiratory gas exchange units; it is thought to begin by 24 to 
26 weeks’ gestation and is completed by 40 weeks’ gestation. [33] The alveolarization 
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stage includes the differentiation and multiplication of alveolar cells. The alveolarization 
stage extends from birth until 3 years of age; lung volume increases mainly because of an 
increasing number of alveoli. Alveoli may still develop up to 8 years of age.[34, 35] In 
contrast, the number of conducting airways is complete at birth; thereafter, the airways 
increase only in size. After alveolar multiplication is completed, lung growth continues in 
size only.[36, 37] Interference with developmental programming of the lung by undesirable 
effects of an environmental factor during any of these phases may affect lung development, 
leading to increased risks of lung disease or decreased ability of gas exchange later in life 
[38] see Figure.1 In the following section, I will describe the factors affecting lung 
development. 
4 7 16 26 Birth
Postnatal (years) 
2-3 11-19
Prenatal (weeks’ gestation) 
Embryonic 
Pseudoglandular
Canalicular
Saccular
Alveolar
Growth
23
Figure 1. Stages of normal lung development 
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1.3.3 Antenatal-prenatal environmental influences on lung development
1.3.3.1 Fetal growth restriction
Intrauterine growth restriction is associated with an increased risk of compromised lung 
development leading to BPD [39] and impaired lung function in children [40] and adults. 
[41] In animals, studies have established that intrauterine growth restriction causes a 
reduction in the number of alveoli, with consequently impaired blood gas exchange which 
persists into adulthood. [42, 43] 
1.3.3.2Maternal smoking and nicotine
Infants of mothers who smoke have reduced respiratory function and are more likely to 
develop wheezing than others. Experimental studies in various animal models have demon-
strated that exposure to nicotine leads to smaller lungs with a reduced number of alveoli. 
[44] There is evidence from animal models that prenatal exposure to nicotine causes 
abnormalities in airway branching, leading to increased airway smooth muscle and collagen 
deposition, reductions in airflow, and airway hyperreactivity.[45] Several epidemiological 
and physiological studies [46, 47, 48, 49] have confirmed the postnatal effects of intra-
uterine smoke exposure in humans, which include disrupted lung function and increased 
respiratory morbidity. Prenatal nicotine exposure is associated with poor lung function at 
birth, which persists into early adulthood. [47, 50] 
Taken together, the results of these studies indicate that nicotine exposure leads to 
persistent reduction of lung capacity for gas exchange. This may contribute to reduced 
exercise capacity as well as poor response to respiratory infections. [51]
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1.3.3.3 Prenatal infection 
Chorioamnionitis is a prenatal inflammatory response associated with bacterial infection of 
the uterus and infiltration of neutrophils into the placenta. Chorioamnionitis causes 
increased concentrations of proinflammatory cytokines such as interleukin (IL) -6, tumor 
necrosis factor alpha, interleukin-1 beta, and IL -8 in the amniotic fluid. This process is 
reported to increase the infant’s risk of developing BPD. [52] 
1.3.4 Postnatal environmental influences on lung development 
1.3.4.1 Prematurity
When birth occurs at 28-32 weeks’ gestation, the lung is in the saccular stage of 
development. During the saccular stage, the lungs start producing surfactant. Surfactant is 
essential after birth as it serves to lower the surface tension at the alveolar air-liquid 
interface and to stabilize the alveoli during expiration. [33] Before 29 weeks of gestation,
the pulmonary surfactant system is immature and infants often require administration of 
exogenous surfactant to prevent alveolar collapse. An immature pulmonary surfactant 
system in combination with structurally immature alveoli is the major cause of respiratory 
distress syndrome (RDS). RDS is common in extremely preterm and very preterm infants, 
leading to a requirement for prolonged respiratory support. [33] Respiratory support in the 
presence of severe lung immaturity is the major cause of lung injury and is associated with 
BPD. [53] 
Moreover, infants born prematurely or with various clinical syndromes may suffer delayed 
development of the lungs and airways, with consequences in later life. [54, 55] Several 
studies have shown that extremely premature children have reduced lung function with 
respiratory disease in later childhood [56, 57, 58] or early adulthood. [55]
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1.3.4.2 Early exposure to hyperoxic gas
Preterm infants born before 30 weeks of gestation are exposed to elevated fractions of 
inspired oxygen (FiO2) for extended periods of time, owing to respiratory insufficiency. 
Exposing the immature lung to hyperoxic gas can initiate the generation of reactive oxygen 
species (ROS). ROS can directly damage DNA and proteins, cause lipid peroxidation, and 
contribute to inflammation [59] and decreased alveolarization. [60]
Studies in rodents have found that neonates exposed to higher levels of FiO2 during the 
saccular and alveolar stages of lung development had fewer and larger alveoli, with altered 
vascular development. Oxygen-dependent loss of vascular endothelial growth factor 
(VEGF) contributed to these changes [61, 62]. The blocking of VEGF signaling disrupted 
postnatal alveolar development. [63,64] Further, the number of circulating endothelial cell 
precursors found in the blood and lung was reduced in neonatal mice exposed to hyperoxia. 
[65, 66] Today, advances in medical practice and the use of exogenous surfactant and 
antenatal steroids have led to reduced mortality in BPD. However, infants born prematurely 
have an increased risk of asthma and are often re-hospitalized when infected with 
respiratory syncytial virus. [67, 68] 
1.3.4.3 Ventilatory support 
Most very preterm infants will need respiratory support due to respiratory distress 
syndrome. This ventilatory support increases the risk of BPD [69]. It has been shown that 
mechanical ventilation alone leads to impaired alveolarization in the very immature lung. 
[70, 71] Several studies have shown an early inflammatory reaction and inflammatory 
cytokines such as IL-8, IL-6 in bronchoalveolar lavage fluid from premature infants who
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develop BPD. [72, 73, 74] Moreover, ventilation in preterm sheep increases inflammation 
and airway injury [75]. 
1.3.4.4 Postnatal growth restriction 
After birth, the lung continues to develop, with increasing numbers of new alveoli. 
Postnatal nutrition and growth may affect the architecture of the adult lung. An animal 
study in adult sheep showed that postnatal growth correlated with the final number of 
alveoli. [76] Poor nutrition and growth in preterm infants could therefore contribute to 
reduced lung function and increased risks of pulmonary illness during childhood and 
adolescence. [77]
1.3.4.5 Early lung infections
Recurrent infections in early life such as respiratory syncytial virus may affect lung 
development, especially when sustained within the critical period of immune system 
development.[78] Several studies [79, 80, 81, 82] have shown that respiratory syncytial 
virus infection was associated with wheezing and bronchiolitis in infants and contributed to 
the development of asthma. The recurrent wheezing may result from losses of pulmonary 
function, lung growth and development due to impaired repair mechanisms. Children are 
most susceptible to respiratory tract infections in their first year of life because of an 
immature immune defense system. [83] This first year also corresponds with the period of 
lung alveolarization; there is therefore an increased risk of altering the development of the 
gas exchange region of the lung. Lower respiratory tract infections have been associated 
with reduced forced expiratory flow at school age. [84, 85] A cohort study has addressed 
the developmental aspect of lung function from childhood to adulthood in relation to early 
lower respiratory tract infections. This study reported an association between early 
infections in the first 2 years of life and reduced lung function in adulthood. [86]
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Figure 2. Stages of normal lung development and factors affecting lung development 
Lung maturation must pass through the cell cycle stages of proliferation, differentiation, 
and apoptosis in order to continue lung remodeling. These cycle stages are dependent on 
the redox potential. 
Since apoptosis is needed for proper lung development and is important to the hypothesis 
proposed in this thesis, the next section will be devoted to the role of apoptosis in lung 
development and to how apoptosis occurs.
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1.4 Apoptosis and lung development 
Several studies have observed apoptotic activity in the various stages of lung development, 
suggesting a role for apoptosis in these processes. [87, 88, 89, 90, 91] During the 
embryonic stage of lung development, apoptosis was found in the peripheral mesenchyme. 
Studies have shown that apoptosis in the canalicular stage at 18 days of gestation leads to a 
progressive increase in epithelial and interstitial apoptosis. [92,88] During late gestational 
development (canalicular, saccular stages), there is lung remodeling with an increase in 
alveolar type II epithelial cell apoptosis and a decrease in cell proliferation. [93, 89] After 
birth (alveolar stage), apoptosis serves as an important process to remove excess cells and 
transform saccules into functional alveoli. [91, 90] Alveolar type II epithelial cell 
proliferation is important because these cells serve as precursors to alveolar type I epithelial 
cells, which cover over 95% of the alveolar surface [94]. This proliferation plays a role in 
the maturation of the air-blood barrier during microvascularization [94]. Also, alveolar type 
II epithelial cells produce surfactant, which decreases surface tension and prevents alveolar 
collapse during exhalation after birth. After alveolarization, excess type II epithelial cells 
decrease in number by differentiating into type I epithelial cells and by apoptosis. [90] 
On the other hand, apoptosis may participate in the development of lung disease. Increased 
apoptosis of epithelial cells would lead to inefficient re-epithelialisation or ineffective 
removal of apoptotic cells. [95]
1.4.1 Mechanisms of apoptosis 
During apoptotic events, cells undergo various morphological changes, including cell 
shrinkage, fragmentation of chromosomal DNA, and the release of apoptotic bodies. The 
mechanisms of apoptosis involve an initiation phase, whereby a stimulus activates caspase 
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activities; these enzymes then induce cell death. [95] Two signaling pathways can activate 
a caspase cascade in mammalian cells: the extrinsic pathway and the intrinsic pathway. 
1.4.2 Apoptosis signaling pathways 
The extrinsic or death receptor pathway involves the activation of death receptors present 
in the cell membrane, such as Fas and tumor necrosis factor receptor 1 (TNF-1). 
Connection of the death ligand to its death receptor leads to activation of an adaptor protein 
called activated death domain and the subsequent activation of procaspase-8 or -10; this 
then activates the caspase -3 leading to apoptosis. [96] 
The intrinsic or mitochondrial pathway is induced in response to stress stimuli, such as 
ROS, DNA damage, irradiation, or reduced anti-apoptotic mitochondrial factors (e.g. Bcl2). 
The intrinsic pathway is triggered by alterations in mitochondrial membrane permeability 
and the consequent release of cytochrome c and other apoptogenic factors (e.g. Bak, Bax, 
Bim) from the inner mitochondrial membrane. Cytochrome c binds with apoptotic 
protease-activating factor 1 (Apaf-1) to form an apoptosome. Subsequently, activated 
caspase-9 and caspase-3 induce apoptosis. [97] 
There is now increasing evidence demonstrating that the endoplasmic reticulum also 
executes apoptosis. Various stressors can impair protein folding and induce endoplasmic 
reticulum stress, thus further exacerbating the endoplasmic reticulum stress which 
transduces apoptotic signals. [98]
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Figure 3. Apoptosis pathways: Activation of caspase-3 is caused by the initiator caspases, 
caspase-8 and/or caspase-9, as part of the extrinsic and intrinsic apoptotic signaling 
pathways.
In the next section, I will demonstrate what we know concerning the apoptosis signaling 
pathway in relation to neonatal lung injury and how excessive apoptosis can contribute to 
BPD. 
1.4.3 Apoptosis in neonatal lung injury or BPD
Although oxygen and mechanical ventilation are important to premature survival, excess 
oxygen and pressure overload from mechanical ventilation are injurious to a newborn’s 
lungs, leading to BPD. [59, 99,100] 
The administration of supplemental oxygen to preterm infants is standard therapy. 
However, exposure to high concentrations of oxygen is a major contributor to lung injury 
and BPD [101]. Exposing the immature lung to hyperoxic gas can initiate the generation of 
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ROS. ROS can directly damage DNA and proteins, cause lipid peroxidation, and contribute 
to inflammation [59] and decreased alveolarization. [60] Several studies have shown an 
early inflammatory reaction and the presence of inflammatory cytokines such as IL-8, IL-6
[72, 73], and transforming growth factor type 1(TGF-1) [74] in bronchoalveolar lavage 
fluid from premature infants who develop BPD. Hyperoxia-induced lung injury is 
considered a major risk factor for the development of BPD. In the developing lung, 
hyperoxia results in epithelial and endothelial cell loss, disordered proliferation, and other 
changes that may hinder alveolar and microvascular development [102]. Thus, ventilatory 
support in very preterm infants also increases the risk of BPD [69]. Indeed, it has been 
shown that mechanical ventilation alone leads to impaired alveolarization in the very 
immature lung. [70, 71]
An elevated apoptotic ratio was found on autopsy in alveolar and bronchiolar cells of 24 
patients with BPD. [103] These data highlight the importance of apoptosis in the 
development of BPD in the premature infant. In fact, growing evidence from animal and 
human studies supports an increase in apoptotic signals.
Lukkarinen et al. [104] showed that preterm infants who had RDS and received mechanical 
ventilation had higher levels of apoptosis, particularly in epithelial cells. 
Similarly, increased levels of epithelial apoptosis have been observed in neonatal mice 
exposed to high concentrations of oxygen [105] and mechanical forces. [106]
Exposure to high concentrations of oxygen in the neonatal period may impair lung growth 
and is a major contributing factor to the development of BPD. [107,108] Cell death from 
hyperoxic injury may occur through either an apoptotic or non-apoptotic pathway. Sharon 
et al. found increased levels of Bax messenger RNA, a gene transcript associated with 
apoptosis, in the lungs of neonatal mice born and raised in 92% oxygen levels. In neonatal 
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mice exposed to hyperoxia, apoptotic cells in the lungs increased with longer exposure 
times. [105] The increase in apoptosis from hyperoxic exposure during a critical period of 
lung development may be an important factor in the impaired lung growth and remodeling 
of BPD.
Li et al. found increased expression of P53, a gene associated with apoptosis, in the lungs 
of neonatal rats born and raised in 95% hyperoxia. These results suggest that 95% 
hyperoxia could upregulate the gene expression of P53, which induces the transcription of 
P21 [109]. Furthermore, P21could lead to cell cycle arrest and inhibit proliferation of lung 
cells. At the same time, P53 could also promote apoptosis of lung cells. Similarly, Das et
al. showed increased apoptosis and expression of P21 and P53 in the premature infant 
baboon model of BPD [110]. Therefore, exposure to high concentrations of oxygen in the 
neonatal period may impair lung growth and be a major contributing factor to the 
development of BPD.
The Fas ligand (FasL) pathway is a system of signaling- and receptor-molecules leading to 
apoptosis. Fas antigen is expressed in various cells and tissues including the lung [111]. 
FasL can be released as a biologically active, death-inducing mediator capable of inducing 
apoptosis of epithelial cells during acute lung injury [112]. In FasL transgenic mice, 
upregulation of Fas-L was associated with dramatically increased apoptosis of alveolar type 
II cells and Clara cells, disrupted alveolar development, decreased vascular density, and 
increased postnatal lethality. [113] These results suggest that inhibiting this pathway may 
lead to novel targets against BPD.
TGF-1 is the most potent promoter of extracellular matrix production. In addition, TGF-1
can induce apoptosis directly in various cells. [114] TGF-1 can mediate apoptosis through 
activation of caspase-3, upregulation of P21, and downregulation of Bcl-2 expression [115,
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116]. However, TGF-1 is also an enhancer of Fas-mediated apoptosis of lung epithelial 
cells [117]. Increased levels of TGF-1 are found in airway lavage samples of infants in the 
early stages of BPD [74]. Moreover, high levels of TGF-1 are associated with more severe 
cases of BPD [74]. In BPD during tissue remodeling, dysregulation of the TGF-1 pathway 
may interact with Fas-mediated epithelial cell apoptosis during the pathogenesis of 
pulmonary fibrosis. Repair after BPD requires the elimination of proliferating 
mesenchymal and inflammatory cells. Failure to clear unwanted cells by apoptosis will 
increase the inflammation [118]. Therefore, apoptosis may have both beneficial and 
detrimental effects during BPD. 
Finally, in animal studies, the infusion of PN without adequate photo protection was 
associated with a lower level of alveolarization (i.e. hypoplasia), the principal characteristic 
of BPD [119]. Moreover, a higher level of apoptosis was observed in lungs with alveolar 
hypoplasia [119]. However, little is known about the biochemical mechanisms involved 
and the present thesis will hopefully lead to a better understanding of this mechanism.
In the following section, I will review the definition and characteristics of BPD, who is at 
risk for developing BPD, differences between old and new BPD, the clinical definition of 
BPD, and finally, the long-term outcomes of BPD.
1.5 Bronchopulmonary dysplasia
BPD is a lung disease of premature infants, characterized by abnormal alveolarization and 
pulmonary vascularization. BPD was first described by Northway in 1967 [120]. He and 
his colleges defined BPD on the basis of clinical, radiographic and pathological findings 
following clinical practices such as aggressive mechanical ventilation and high levels of 
oxygen in RDS [121]. Today this lung disease is called classic or old BPD, which was 
characterized by lung inflammation, airway injury, lung fibrosis, and oxidative stress. 
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This definition has become less relevant in current practice, with improved care of RDS 
and the survival of very tiny babies. In 2001, the National Institute of Child Health and 
Human Development defined BPD as the need for supplemental oxygen at 36 weeks of 
PMA, with severity based on oxygen concentration [122]. Infants requiring supplemental 
oxygen at 28 days of life but not at 36 weeks’ PMA were considered to have mild BPD. 
Infants requiring supplemental oxygen at 28 days and at a fraction of inspired oxygen 
(FiO2) < 0.30 at 36 weeks’ PMA were considered to have moderate BPD. Infants requiring 
supplemental oxygen at 28 days, and mechanical ventilation and/or FiO2 > 0.30 at 36 
weeks’ PMA were considered to have severe BPD [123]. New BPD is characterized by an 
“arrest” of alveolar development, with fewer alveoli, little to no airway injury, and no lung 
fibrosis.
Table 3. BPD severity.
Types of BPD Gestational age < 32 weeks *HVWDWLRQDODJH weeks
Mild BPD Breathing room air at 36    
weeks’ postmenstrual age
Breathing room air by  56 
days’ postnatal age 
Moderate BPD Need for < 30% oxygen at 36 
weeks’ postmenstrual age
Need for < 30% oxygen at 56 
days’ postnatal age
Severe BPD 1HHGIRUR[\JHQDQGRU
mechanical ventilation at 36 
weeks’ postmenstrual age
1HHGIRUR[\JHQDQGRU
mechanical ventilation at 56 
days’ postnatal age
Adapted from Mosca et al.
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Table 4. Comparisons between old and new BPD 
Old BPD New BPD
Gestational age 32 weeks of gestation 24-26 weeks of gestation
Birth weight average 1900 g 600 g
Infants at risk More mature infant Extremely low gestational age
Airway injury Severe Mild
Fibrosis Severe Mild
Alveolar development Well-developed Arrested development
Causes Oxygen toxicity and
mechanical ventilation
Interference with development
Adapted from Mosca et al.
It is important to know that these tables summarizing the differences between the two forms 
of BPD (old vs new) and underlying the causes for BPD have been published before my 
work. Moreover, my work highlights the clinical importance of PN, which increases the 
risk for BPD; the arrested alveolar development may be the result of exaggerated apoptosis. 
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Figure 4. Histological findings comparing old and new BPD. 
1.5.1 Consequences of bronchopulmonary dysplasia
Compared to full-term infants, preterm infants with BPD are more susceptible to recurrent 
wheezing and lower respiratory infections that require frequent hospitalizations during the 
first 2 years after birth. [125,126] In addition, several studies have shown abnormalities of 
pulmonary function during infancy in infants who had BPD. [127] Indeed, BPD is 
associated with a significant reduction in pulmonary function and exercise capacity and an 
increased risk of respiratory symptoms including cough, wheeze, and asthma in children 
Old BPD: Airway injury, 
inflammation and fibrosis due to 
mechanical ventilation and oxygen 
toxicity.
New BPD: Alveolar hypoplasia 
leading to fewer and larger alveoli 
and impaired vascular development. 
Normal healthy lung 
with normal alveoli.
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aged 7 to 12 years.[128,129] Finally, preterm infants with BPD commonly develop 
neurodevelopment disorders, growth retardation, and educational difficulties at school 
age.[130,131] 
1.5.2 Treatment and prevention of BPD
Regardless of advances in the treatment of neonatal respiratory disorders such as
pulmonary surfactants and corticosteroids, diuretics, ventilatory supports, and in prophylaxis 
to accelerate lung maturation and reduce neonatal respiratory disorders, BPD remains a 
major complication for preterm infants [132]. The pathogenesis of BPD is multifactorial 
and highly complicated. Several factors are known to influence the incidence of BPD, 
including low gestational age at birth, male sex, inflammation, infection, and oxygen 
supplementation. [10] Recently, PN has been reported to increase the risk of BPD [133]. 
Oxidative stress is implicated in the etiology of all these factors.
BPD
Oxygen
Ventilation
Inflammation 
Sex and 
gestational age
Oxidative 
stress
Figure 5. Factors implicated in the incidence of BPD: environmental factors such as 
inflammation, oxygen supplements, ventilation and oxidative stress; and other internal 
factors such as sex and gestational age.
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Prevention and treatment of BPD will need a comprehensive approach including all the 
factors and mechanisms leading to this chronic lung disease. Although oxidative stress has 
been suggested, the causative molecules and mechanisms involved in the development of 
this disease are still unclear. 
The present thesis aims to further our understanding of the mechanistic process of BPD 
development and the causative molecules involved in this chronic lung disease. This 
knowledge would help avoid or minimize the extent of this disease, a disease that may have 
consequences in later life, including persistent lung abnormalities.
In the following section, I will describe oxidative stress in this population, specifically the 
sources of oxidant molecules and the antioxidant defense system. 
1.6 Oxidative stress 
Oxidative stress results from an abnormally high level of oxidative molecules in a cell or 
organ. This may be caused by a low capacity of antioxidant defenses, an excessive 
production of oxidant molecules, a high load of exogenous oxidant molecules, or all of the 
above. ROS as shown in Table 5 are produced as a normal consequence of ATP production 
in the mitochondria and by intracellular specific enzyme systems. Alternatively, they can 
be derived from external sources such as inhaled oxygen and pollutants. An increase in 
intracellular levels of these oxidants will eventually damage cellular lipids, proteins, and 
DNA and lead to impaired cell function and finally, cell death. Thus oxidative stress plays 
an important role in the development of several pathological complications. [134,135] 
Recently, oxidative stress has been redefined as an imbalance between pro-oxidants and 
antioxidants, leading to macromolecular damage and/or disruption of redox signaling (see 
below) [136]. It is proposed that this latter may induce pathological conditions.
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1.6.1 Oxidants
An oxidant can be defined as a substance that accepts electrons in chemical reactions. 
Oxidants are formed as a normal product of aerobic metabolism. These oxidants can be 
produced in excessive rates under pathophysiological conditions. They include radical and 
nonradical oxidants. Radical species include the superoxide anion, hydroxyl radical, and 
nitric oxide whereas nonradical oxidants include hydrogen peroxide, hydroperoxyl fatty 
acids, and aldehydes [137].
Table 5. Examples of reactive oxygen species and corresponding antioxidants
Radical Antioxidant
Superoxide anion (O2-) Superoxide dismutase
Singlet oxygen Ǻ-carotene
Hydrogen peroxide (H2O2) Catalase, glutathione peroxidase, glutathione
Hydroxyl radical (OH•) Vitamins C and E
Peroxide radical (LOO•) Vitamins C and E
Hydroperoxyl radical (LOOH) Glutathione transferase, glutathione peroxidase
Adapted from Davis et al. [138].
1.6.2 Antioxidants 
An antioxidant can be defined as any substance that avoids or eliminates oxidative damage 
to a target molecule [139]. Antioxidants can be classified into 3 categories: primary, 
preventing oxidant formation; secondary, scavenging the oxidants; and tertiary, repairing or 
removing damaged molecules. 
28
Antioxidants include enzymatic antioxidants such as catalase, glutathione peroxidase (GPx)
and glutathione transferase, and non-enzymatic antioxidants such as vitamin C, vitamin E, 
glutathione, trace minerals and fatty acids.
1.7 Oxidative stress and antioxidant defense systems of premature infants
At birth, the fetus transfers from an intrauterine hypoxic environment with an arterial 
partial pressure of oxygen (PaO2) of 20-25 mm Hg to an extrauterine environment with a 
PaO2 of 100 mm Hg. In term infants, there is an increase of protective antioxidant enzyme 
activity immediately prior to birth. However, the premature infant is prone to oxidant-
induced damage principally for two reasons: first, inadequate concentrations of 
antioxidants; and second, the ability to increase synthesis of antioxidants in response to 
hyperoxia or other oxidants is insufficient [140]. Frank et al showed that the activity of 
antioxidant enzymes in the lung, such as GPx and catalase, increases as a function of 
gestational age in several animal species (rabbit, guinea pigs, rats and hamster) [141]. 
Therefore, their activity increases in the last 15% of gestation. This finding parallels the 
premature infant’s complications which are inversely proportional to GA. Similarly, serum 
levels of non-enzymatic antioxidants such as vitamins C and E are reduced in preterm 
infants as compared to term controls [142,138]. The same is true of glutathione, a key 
antioxidant: the concentration in cells from endotracheal aspirates increases during 
gestation [143]. 
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Oxidative Stress and Birth
Oxidants Reductants
Term infant has to balance oxidants and 
reductants
Premature infant has imbalance/ 
Injury
Figure 6. Oxidative stress and birth.
Reductants: catalase, GPx, glutathione and vitamins E, A, C
Oxidants in term infants: inspired oxygen
Oxidants in premature infants: O2, parenteral nutrition, infection, and inflammation
GSH is considered a key element of antioxidant defenses. It participates in detoxification of 
peroxides and radicals: first, as an electron donor for the reduction of peroxides through the 
action of glutathione peroxidases; second, as a recycler of radical scavengers such as 
ascorbate and tocopherol [144]. In addition, glutathione is recognized as the buffer of the 
intracellular redox environment [145]. Recently, Chessex and others have reported a strong 
correlation between the severity of BPD in premature infants and the redox potential of
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glutathione measured in their blood [146]. Hence, a perturbation of glutathione metabolism 
is suspected to induce BPD development.
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Figure 7.Glutathione structure Glutathione in its reduced form is the tripeptide L-Ȗ-
glutamyl-L-cysteinylglycine. Adapted from [147]
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Figure 8. Disulfide (oxidized) form of glutathione. Adapted from [147]
In the next sections, I will discuss the metabolism of glutathione in preterm newborns and 
the impact of glutathione perturbation on the redox potential.
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1.7.1 Glutathione metabolism in premature infants
In vivo, the regulation of GSH (J-glutamylcysteinylglycine) takes place in the liver [148]. 
The liver is considered both a synthesizer and exporter of GSH. It provides 90% of the 
glutathione supply in blood [149,150]. Indeed, the liver has a great capacity of glutathione 
synthesis for its own needs and for export via the sinusoidal multidrug resistance proteins 
(MRP3). As GSH does not cross freely through the cellular membrane, J-glutamyl 
transpeptidase plays an important role in supplying cells with needed substrates for GSH 
synthesis. Gamma-glutamyl transpeptidase is an enzyme anchored in the cell membrane 
with its catalytic site in the extracellular milieu. [151] This omnipresent enzyme transfers 
the J-glutamyl moiety of glutathione present in plasma (from the liver) onto a second 
amino acid, forming two dipeptides (J-glutamyl amino acid and cysteinylglycine). These 
dipeptides are absorbed by cells and hydrolysed into free amino acids. Free cysteine 
availability in cells is a limiting step for de novo synthesis of GSH. [152] Indeed, the 
physiological intracellular concentration of cysteine is close to the Michaelis-Menten 
kinetics constant (Km) of the first enzyme of the glutathione synthetic pathway, J-
glutamylcysteine synthetase, whereas the concentrations of the two other amino acids 
(glutamate and glycine) are far higher than the Km of these enzymes. [153] Therefore, in 
circulating blood, the action of Ȗ-glutamyl transpeptidase on glutathione deriving from the 
liver favours the increased concentration of cysteine in cells, favouring in turn, the cellular 
synthesis of glutathione. The activity of J-glutamyl transpeptidase matures in the first 
postnatal days of premature infants. [154]
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Figure 9. Extracellular GSH hydrolysis is catalysed by Ȗ-glutamyl transpeptidase. The 
amino acid precursors for GSH synthesis, cysteine and glycine, are transported via 
membrane carriers for intracellular GSH synthesis. GSH synthesis from glutamate, cysteine 
and glycine occurs within the cytosol via two ATP-dependent steps that are catalysed by 
glutamate-cysteine ligase (Ȗ-GCL) and glutathione synthase (GS). Distinct GSH pools are 
compartmentalized within the cytosol, mitochondria, nucleus and endoplasmic reticulum.
The low glutathione levels observed in premature infants is not explained by an immaturity 
of the capacity for synthesis, which is fully active even in neonates born at 26 weeks of 
gestation. [154] The deficiency seems to derive from the availability of cysteine for GSH 
synthesis or lack thereof. [143]This hypothesis may be explained by an insufficient 
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concentration of cysteine or glutathione in the circulation. The cysteine can be provided by 
nutrition. Premature infants < 29 weeks of gestation are essentially fed intravenously, by 
way of parenteral nutrition. However, the instability of cysteine in solution limits its 
enrichment in PN. [155] In addition, the cellular uptake of cysteine is immature in this 
population. [143] Therefore, the main source of cysteine for glutathione synthesis remains 
the transformation of methionine into cysteine. Indeed, this essential amino acid is known 
to be primarily metabolized in the liver; it serves as the endogenous source of cysteine and, 
consequently, of glutathione synthesis. [156]
The first enzyme involved in the transformation of methionine into cysteine is methionine 
adenosyltransferase (MAT). [148,157] However, PN as used in the clinical setting is 
contaminated with about 350 PM peroxides and MAT contains redox-sensitive thiols 
essential for enzymatic activity. I have shown in the course of my Master’s thesis that the 
infusion of H2O2 at concentrations similar to those measured in PN induces a lower activity 
of MAT in animals. Both H2O2 and PN lead to a reduction of glutathione levels in the liver 
as well as in whole blood. This work was published in Free Radical Biology and Medicine
in 2012. [158] 
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Figure 10. Transformation of methionine into cysteine, the rate-limiting amino acid for 
glutathione synthesis.
1.7.2 Redox potential of glutathione
In addition to its antioxidant capacity, glutathione is considered the buffer of the 
intracellular redox potential. The redox potential of the cell influences electron transfer 
between chemical species and thus affects metabolism to a large degree. Redox potential 
can be estimated from the concentrations of both GSH and GSSG, with the Nernst equation 
ǻE =ǻE°࣭ (RT/nF) ࣭ log ([GSH] 2/ [GSSG]) mV at 25oC and pH 7, where R is the gas
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constant, T is the temperature (in Kelvin), n is the number of transferred electrons, F is the 
Faraday constant, [GSH] is the concentration of reduced glutathione and [GSSG] is the 
concentration of disulfide glutathione. [159]
The redox potential is associated with the biological status of the cell. During cellular 
development, cells must pass through several cell cycle stages in order to continue 
remodeling. These cycle stages are conditioned by the redox potential. For example, cells 
pass from proliferation to differentiation and apoptosis when the redox potential shifts from 
a reduced to an oxidized state.[159] During the proliferation phase, where the redox value 
is highly reduced, cells have a high metabolic rate leading to increased generation of ROS. 
These ROS shift the redox potential toward an oxidized state, provoking the differentiation 
phase. An even greater oxidized status induces apoptosis. An oxidized redox potential will 
activate redox-sensitive factors such as nuclear factor erythroid-derived 2 (Nrf2) which are 
responsible for the transcription of the gene for Ȗ-glutamylcysteine synthetase, the first
enzyme responsible for the glutathione synthesis, and glutathione reductase (enzyme 
involved in GSSG recycling). In this way, activation of Nrf2 leads to a higher concentration 
of GSH and a more reduced redox potential, and a new cell cycle begins. Hence oscillation 
in redox potential is essential for tissue remodeling.
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Figure 11. Activation of Nrf2 by oxidative stress
The redox potential is also dependent on the action of GPx and glutathione reductase (GR). 
GPx plays a very specific role in cellular metabolism, particularly in the removal of LOOH, 
terminating the lipid peroxidation chain reaction and protecting biological membranes. In 
mammalian tissues, four isozymes of GPx (GPx 1, GPx2, GPx3 and GPx4) have been
identified. Mammalian isozymes GPx1, GPx2 and GPx3 reduce H2O2 and peroxides of free 
fatty acids whereas GPx4 reduces peroxides of phospholipids and cholesterol.
GPx, an enzyme whose catalytic action is dependent on the micronutrient selenium (Se), 
catalyzes the reduction of H2O2 and other organic peroxides to water and corresponding 
alcohols, respectively. [160] This reaction requires two molecules of GSH as reducing 
substrate. The product of this reaction is GSSG. The activity of GPx is tightly controlled
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since any modification would lead to altered intracellular concentrations of hydrogen 
peroxide. [161] As a result of this GPx reaction, the intracellular level of GSSG rises. This 
will affect the cellular redox potential. Normally, GSSG is then reduced back to GSH by 
the action of GR in the presence of NADPH as electron donor. If the activity of GPx is 
greater than that of GR, the accumulated GSSG will be actively exported to maintain the 
intracellular redox potential [162]. In this case, lower intracellular levels of GSH result, 
affecting the activity of GPx because the normal level of GSH in cells is at the level of the 
Km of GPx. A lower level of GSH leads to a lower activity of GPx, allowing intracellular 
levels of H2O2 to rise. To prevent loss of glutathione, the cell stimulates de novo synthesis 
of GSH and recycles the GSSG into GSH by GR [163].
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H2O2
H2O
Glutathione     peroxidase Glutathione     reductdase
NADPH + 
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NADP+
Figure 12. Redox cycle 
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1.7.3 Main source of oxidative stress in premature infants 
1.7.3.1 Oxygen supplementation 
Fetal life in utero is maintained under low oxygen pressure. After birth, the baby breathes 
room air; there is a rapid increase in oxygen intake. Infants born at term are adapted to face 
this situation [138]. Premature infants, as mentioned above, are born with insufficient 
antioxidant defenses to cope with this oxygen stress. 
Briefly, inspired oxygen (O2) is a diatomic molecule with two free electrons. The standard 
redox potential of ½ O2: H2O is high in biology (+0.82 V). Oxygen is easily reduced in 
water through various mitochondrial protein complexes. During these processes, about 1-
3% of O2 will be partially reduced, with generation of superoxide anions (O2•-) [164]. 
Similarly, dissolved O2 can accept an electron from several donors such as polyunsaturated 
fatty acids or ascorbic acid, generating a superoxide anion. This spontaneous reaction
results in the formation of oxidized vitamin C and/or by-products of fatty-acid oxidation 
such as lipid peroxides, aldehydes, and isoprostanes [133]. Superoxide dismutase (SOD) 
converts two superoxide anions into H2O2 and oxygen. H2O2 can be reduced to H2O by two 
enzymes, catalase or GPx. [165] In premature newborns with immature antioxidant 
defences, however, the effects of peroxide are disastrous. [166] High intracellular 
concentrations of H2O2 switch the redox potential to a more oxidized status, which could be 
an early factor leading to the development of several pathological neonatal complications.
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Figure 13. Different oxidants and antioxidant enzymes. O2: Oxygen, O2•- , Superoxide 
anions, H2O2 : hydrogen peroxide, Fe : iron, HO
.: Hydroxyl radical , SOD: Superoxide 
dismutase 
Thus, in neonatal units, high oxygen and the administration of PN both have an impact on 
BPD, sharing H2O2 as a common factor. In fact, Mohamed I et al. from our team have 
shown that high FiO2 and duration of PN have an additive impact on the prevalence of BPD 
[167].
1.7.3.2 Parenteral nutrition 
As mentioned earlier, premature infants depend on PN to meet their nutritional needs. 
Although PN is essential for growth and development, PN is also associated with 
undesirable effects caused by oxidant molecules generated in the solution. [168]
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In fact, PN represents the second major source of oxidant molecules in the premature 
population because PN is contaminated with peroxides. In PN solution, the dissolved 
oxygen causes the oxidation of polyunsaturated fatty acids, amino acids and vitamin C. 
Several molecules are formed as a result of these interactions. [169] Among them are 
aldehydes and hydroperoxides derived from lipid peroxidation, and H2O2 [170], as well as 
ascorbylperoxide (AscOOH) from ascorbic acid. [171] Because PN contains a photo-
sensitive compound, riboflavin, these reactions are catalyzed by ambient light. The 
interaction between oxygen and ascorbate in the presence of photo-excited riboflavin, the 
last two derived from the parenteral multivitamin preparation, generates H2O2 and 
AscOOH. [172]
Furthermore, these reactions contribute to the loss of fatty acids, amino acids, and 
antioxidant vitamins such as ascorbate. Even perfect photoprotection of the solution 
reduces the concentration of peroxides by only half. However, this reduction is sufficient to 
induce detrimental metabolic changes in children. [173,170] Unfortunately, it is difficult to 
reach such photoprotection in the clinical setting. Because even a few minutes of light 
exposure is sufficient to generate significant amounts of oxidant molecules in PN solution, 
photoprotection must be initiated during PN preparation in the pharmacy without any 
exposure to light until it reaches the bedside, where the bag and delivery tubes must be 
fully covered.
1.7.4 Oxidative stress markers in the premature infants 
The infusion of PN without adequate photoprotection is associated with several markers of 
oxidative stress in premature infants, such as high concentrations of peroxides in the urine. 
[174] Moreover, urinary 8-hydroxy-20-deoxyguanosine has been reported to be higher in 
preterm than term infants. [138] As with the redox potential of glutathione in whole blood, 
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urinary dityrosine and isoprostane are elevated in premature infants as compared to adults. 
[146]
1.7.5 Relation between oxygen supplementation and BPD
Although oxygen is considered a strong oxidant and oxidative stress is suspected to induce 
BPD, recent reports suggest the absence of a relationship between them. Recently, 
advances in clinical practice such as the use of surfactant and continuous positive airway 
pressure have led to a reduction in oxygen supplementation. Stroustrup et al. documented 
that the reduction in oxygen use in neonatal units between 1993 and 2006 has reduced the 
incidence of BPD by 30% [175]. Currently, the prevalence of BPD in Canada is 45% in this 
population (data from Cable News Network (CNN)). In animal studies (newborn preterm 
baboons), the reduction in the fraction of inspired oxygen had no significant impact on the 
levels of fibrosis and alveolar hypoplasia. [176] A 2010 clinical study of 1316 infants born 
at less than 28 weeks of gestation reported a non-significant effect of decreased fraction of 
inspired oxygen on the incidence of BPD. [177] In the study, oxygen supplementation had 
been calibrated to reduce blood oxygen saturations from 91-95% to 85-89%.
Briefly, oxygen supplementation remains an important factor in BPD development [167] 
but its reduction in the clinical setting is at its limit. The second main source of oxidants
leading to BPD is PN.
1.7.6 The relation between PN and BPD
The infusion of PN to premature infants without adequate photoprotection is associated 
with several markers of oxidative stress such as urinary peroxides [174] and an oxidized 
redox potential in whole blood. [146] This stress is associated with a greater incidence of 
several pathological complications observed in this population, such as BPD. In clinical 
studies, photoprotection halves the concentration of peroxides in solutions of PN received 
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by children and decreases the incidence of BPD in premature infants born before 32 weeks 
of gestation. [178, 166]
In animal studies, the infusion of PN without adequate photoprotection was associated with 
a lower level of alveolarization (hypoplasia) [119], the principal characteristic of BPD. 
Moreover, a higher level of apoptosis was observed in lungs with alveolar hypoplasia.[119]
This alveolar hypoplasia was not associated with H2O2-contaminated PN but with the 
interaction between ascorbate and riboflavin. [119] Because this interaction also generated 
AscOOH [172], this molecule was suspected to induce the loss of alveoli in animals and to 
induce BPD development in premature infants. What is this molecule?
1.7.7 Ascorbylperoxide (AscOOH)
Vitamin C works as an antioxidant by donating 2 electrons to an oxidant molecule, such as 
oxygen, thus protecting other compounds from oxidation. [179] Semi-dehydroascorbate, an 
ascorbyl radical, is formed after the loss of one electron. Loss of a second electron forms 
dehydroascorbate (DHA). In vivo, DHA is reduced back to ascorbate by many mechanisms 
within the cell, including direct reduction by GSH and enzymatic reduction by various thiol 
transferases or NADPH-dependent reductases [180]. In vitro, such as in PN, DHA is 
hydrolyzed irreversibly to diketogulonate. 
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Figure 14. Molecular structure of L-ascorbate and dehydroascorbate, an oxidation product 
formed by the loss of 2 electrons adapted from [181]
In PN, ascorbate reduces the oxygen to hydrogen peroxide. When exposed to light, the 
H2O2 is split into a hydroxyl anion (HO-) and HO•. Subsequently, this radical favours the 
opening of the lactam ring to form a peroxide species, as shown in Figure 15. This new 
molecule is 2,3-diketo-4-hydroperoxyl-5,6-dihydroxyhexanoic acid [172], or 
ascorbylperoxide. Because this molecule was suspected to be involved in BPD 
development, it is at the heart of my work.
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Figure 15. Generation of ascorbylperoxide from dehydroascorbate. Adapted from [172]
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2. Hypothesis and objectives 
The general hypothesis was that PN as administered in neonatal units is a major source of 
oxidative stress that contributes to the development of BPD. Based on previous works, the 
specific hypothesis of the thesis was that ascorbylperoxide, an oxidized form of the 
dehydroascorbic acid spontaneously generated in PN, disrupts alveolar development. The 
main mechanism of action is an inhibition of the transformation of methionine into cysteine 
in the liver, leading to a lower glutathione synthesis in the liver as well as in peripheral 
tissues such as lung. Lower GSH concentrations favour a shift of redox potential to a more 
oxidized state and consequently, to exaggerated apoptosis. If our hypothesis is correct, the 
addition of glutathione to PN would help detoxify ascorbylperoxide through the action of 
glutathione peroxidase and prevent the deleterious impact of PN.
The general objective was to investigate the biochemical mechanisms linking PN to the 
development of BPD in premature newborns and to propose a nutritional alternative that 
would prevent the deleterious impacts of PN in lungs of this animal model. 
The specific objectives were:
1- To assess, in newborn guinea pigs, the effect of intravenously infused ascorbylperoxide 
on the metabolic axis redox potential of glutathione in the lung; specifically, apoptosis 
and the alveolarization index. This objective was reached by infusing increasing doses 
of ascorbylperoxide in presence or not of H2O2 (peroxide generated in PN) during 4 
days.
2- To study the impact of ascorbylperoxide and the redox potential on the activity of MAT 
in the liver; methionine adenosyltransferase is the first enzyme in the metabolic cascade 
from methionine to cysteine. This objective was reached by investigate mechanisms of
inhibition.
46
3- To try to prevent the deleterious impact of PN or ascorbylperoxide infusions on the lung 
by improving glutathione status. This objective was reached by adding glutathione in 
infused solutions.
33.Methods   
3.1 Guinea pigs as an animal model
Our model is newborn guinea pig infused during 4 days with various solutions containing
PN components (concentrations closed to what is administered in clinical neonatal unit)
through a catheter in jugular vein.   Guinea pigs and humans are dependent on vitamin C, a 
strong antioxidant, they are unable to synthesize this vitamin. This is an essential 
characteristic when we study mechanisms related to oxidative stress [182, 183]. Also it is 
an accessible animal model for the study of neonatal PN because at three days of life, the 
size of its body is sufficient for insertion of the smallest catheter of the world in its jugular 
vein, by this age; their glutathione development is not complete, similarly to humans [184, 
185].
The problematic of PN is observed mainly in premature newborns. Clinical studies on the 
impact of PN are difficult since no control existed, premature infants of the same 
gestational age without PN or PN without peroxide do not exist. By choosing a term 
newborn animal, we can separate the impact of PN from prematurity [184]. Similarly to 
premature infants on PN, several markers of oxidative stress have been measured in this 
animal model on PN [186]. The absence of photo-protection of PN induced a loss of 
alveoli, a characteristic feature of the bronchopulmonary dysplasia such observed in 
premature infants [187].
Additionally, by choice, all the animals in our experiments are males. Lavoie has shown 
[143], in cells extracted from endotracheal aspirates from the babies, that the increased 
curve of glutathione levels in function of the gestational age is slower in boys. These results 
suggesting that the baby girl is potentially better protected against an oxidative stress than 
boy. Sex is an important determinant of the incidence of BPD among premature infants, 
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and boys are have much higher incidence to this disease. In addition the recent published 
results demonstrat that there is a correlation between this disease and the redox potential of 
the glutathione [146]. Thus this the main reason for choosing male animals to examine our 
hypothesis with the population that is more vulnerable for oxidative stress. 
At three days of life Hartley guinea pigs (Charles River Laboratories, St.Constant, Quebec,
Canada) , were anesthetized by using ketamine (50mg/mL;0,18mL/100g) and xylazine 
(20mg/mL; 0,05mL/100g) in order to fix a catheter (Luther Medical Products, Tustin, CA) 
in jugular vein. The catheter was placed and externalized in the scapular region, with a 
branch connected to the infusion system. The studied intravenous solutions were infused 
continuously through the catheter at rate of 22 mL / 100 g body weight / day. The solutions 
were changed daily. 
After 4 days, at seven days of age, animals were sacrificed for collection of lungs. After 
ligation of right bronchi, the left lung was filled with a solution of 10% formalin in PBS at 
a pressure of 10 cm, and stored in the same solution for histological preparation. The right 
lung was removed, processed, aliquoted and stored at -80oC until biochemical 
determinations. The urine samples were collected in the last day of the protocol for the 
determination of ascorbylperoxyde concentration. These protocols, accepted by the 
Institutional committee for good animal practice in research, were carried out in accordance 
with the Canadian Council of Animal Care guidelines. 
The protocols and statistical method of my thesis are precisely described in the three 
articles. However, some biochemical and histological methods are abbreviated in those 
articles here is the details of abbreviated methods of the articles.    
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3.2 Ascorbylperoxide generating system 
Knafo et al., [172] has identified ascorbylperoxyde in solution of parenteral nutrition. This 
molecule is new and the pure molecule does not commercially exist. Ascorbylperoxyde can 
be obtained by mixing the following molecules: P0DVFRUEDWHȝ0+2O2 + 30 
ȝ0ULERIODYLQS+7KHVROXWLRQZDVLQFXEDWHGDWURRPWHPSHUDWXUHZLWKVWURQJVWLUULQJ
under ambient light exposure (75 foot-candle) for 48 hours.  The control solution was 
obtained by a similar system, but without ascorbate. The solutions were treated 20 min 
with100 U/mL catalase and filtered against a 30 kDa filter Centricon Plus-20 (Millipore 
Corporation); FOX assay was used to ensure the absence of H2O2.  This generating system 
SURGXFHG D VROXWLRQ RI  ȝ0 DVFRUEylperoxide. Following dilutions in HPLC water 
VROXWLRQVRIDQGȝ0DVFRUE\OSHUR[LGHKDYHEHHQPDGH
3.3 Ascorbylperoxide measurement    
The quantification of ascorbylperoxide in these solutions as well as in animals urine were 
assessed by using Agilent LC/MS 1100 mass spectrometer as mentioned in Knafo et al.,
[172]. Urine samples were centrifuged 1 min at 7000 g. Five ȝL of 2.5 mM OTC (an 
internal standard in this assay, because its molecular weight is near to the molecular weight 
of ascorbylperoxide moreover this molecule is not produced in humans) was added to 95 
ȝL of sample and 4 ȝL of this solution was injected on LC column ZORBAX Eclipse XDB 
C18 (Agilent). The elution was performed with isocratic mixture of ammonium acetate 10 
mM (pH 7): acetonitril (1:1) at 0.4 mL/min. Retention time was 2.6-2.8 min for 
ascorbylperoxide and 4.0 – 4.3 min for OTC. Ascorbylperoxide and OTC was quantified by 
monitoring ion abundance at m/z 207 (ascorbylperoxide), 147 (OTC) and 293 (OTC dimer) 
from electrospray ionization mass spectrometry (Agilent 1100 single quadrupole) (negative 
mode, 25V, source temperature of 350°C, nitrogen nebulizer gas flow of 12 L/min). Total 
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OTC abundance (abundance at 147 m/z + 2 fold abundance at 293) was used as internal 
standard [171].
3.4 Determination of peroxides 
Total peroxides were determined by following at 560 nm the generation of chromophore 
from the complex Fe3+-xylenol orange [188,189]. The principle is based on the Fenton 
reaction in which ferrous ion (Fe2+) is oxidized in presence of H2O2, or other peroxides, in 
its ferric form (Fe3+). Thus, diluted PN was mixed with reactive solution containing 22.5 
mM H2SO4, 90 ȝM xylenol orange, 225 ȝM FeCl2, and 3.6 mM 2,6-di-tert-butyl-4-
methylphenol in methanol. After 30 min of incubation, at room temperature, the solutions 
were centrifuged at 5500 × g for 3 min). The absorbency of the supernatant was read at 560 
nm. The results were expressed in ȝM. H2O2 was used for the external standard curve.
3.5 Protein determination 
Protein was measured by Bradford method, the principle of this technique is a dye-binding 
reaction to protein with a differential color change of a dye (Coommassie) occurs in 
response to the protein concentrations. The absorbance was detected at 595nm. The pellets 
from different tissues were solubilized with 1N NaOH at 37 °C for 2 hours. Addition 
dilution (1 /250) was made and the diluted samples were transferred to spectrophotometric 
cuvettes. Bradford reagent previously diluted (1 / 5) with pure water was added. Samples 
were incubated 10 minutes at room temperature. The absorbance values were compared to 
the curve of bovine serum albumin (BSA; 0 – SJȝ/
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3.6 Alveolarization index
At the time of the sacrifice the right lung and left lung were separated. The right lung was
isolated by ligation of the right bronchus following an incision in the trachea. The left lung 
was filled with 10% formalin at 10 cm pressure; the lungs were stored in formalin until 
histological preparation. Histological slides were prepared by the pathology service of the 
CHU Sainte-Justine. Hematoxilin-eosin coloration was used. The mean number of 
intercepts between a standardized straight-line and histological structure (200X 
magnification) on four different fields were used as an index of alveolar counts [119]. The 
right lung was collected, sampled, prepared and frozen at -80 oC until biochemical 
determinations. 
3.7 GSH and GSSG levels 
Immediately after sampling, 0.25 g of lung was mixed with 5 volumes of 5% (w/v) freshly 
prepared metaphosphoric acid. The lung sample was homogenated on ice during 20 
seconds with Polytron (Biospec Products, Bartlesville, OK, USA). Thereafter, they were 
centrifugated for 3 min at 10000 RPM. Supernatants (for glutathione determinations) and 
pellets (for protein determination) were separated and frozen at -80°C until the day of the 
assay. Reduced (GSH) and disulfide (GSSG) forms of glutathione were separated by 
FDSLOODU\ȝPîFPVLOLFDHOHFWURSKRUHVLVP0ERULFDFLGP0%LV–Tris buffer, 
pH 8.4, 28°C, 18 kV) and were detected at 200 nm on a P/ACE MDQ system (Beckman 
Coulter). GSH and GSSG were used as external standard curves. The redox potential was 
calculated by using the Nernst equation (25ºC, pH 7): Ehc = -240-(59.1/2) log ([GSH] 2/ 
[GSSG]) mV [158].  For this calculation, we assumed that the density of the tissue is one.
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3.8 Determination of glutathione peroxidase activity 
Glutathione peroxidase activity was measured by mixing the solution with reactive 
solution (250 mM Tris, 0.1mM EDTA-Na 2, 1 mM GSH, different solutions of AscOOH,
4.8 U/mg GR, and 0.1mM NADPH, pH 7.6). Determination of the glutathione peroxidase 
activity is based on the following principle 
*6+7%+ĺ*66*%22+
Then GR reduces the GSSG to complete the cycle: 
*66*1$'3++ĺ*6+1$'3
The decrease in NADPH absorbance measured at 340 nm during the oxidation of NADPH 
to NADP+ is indicative of GPx activity. Slope of the drop of absorbance recorded during 5 
minutes was quantified using the NADPH molar extinction coefficient of 6.22 mMícmí.
The activity was expressed as ȝmol NADPH oxidized/min/mg protein at 30C° [143].
3.9 Nuclear and cytoplasmic extraction 
Lung tissue weight is ranging 0.6-0.9 g for one animal. It is too small to do several 
determinations such as redox potential, enzyme’s activities and Western blot of several 
proteins.  Thus I have made one extractions (0.1 g of lung tissue) to do several protein 
expression by Western blot. The extractions were made as follow.
Cytoplasmic and nuclear extracts were isolated by using a commercially nuclear and 
cytoplasmic extraction kit (Pierce Biotechnology, Rockford, IL, USA). According to the 
manufacturer’s protocol, tissue was thawed and washed with PBS (pH 7.4). Then 0.1 g of 
OXQJWLVVXHZDVKRPRJHQDWHGLQȝ/RI LFHFROGF\WRSODVPLFH[WUDFWLRQUHDJHQW-1 for 
 PLQ DQG  ȝ/ RI LFH-cold cytoplasmic extraction reagent-2 for 1 min,. After 
centrifugation at 16,000g for 5 min, the supernatant (cytoplasmic extract) was stored on ice,
ZKLOHWKHLQVROXEOHSHOOHWIUDFWLRQZDVUHVXVSHQGHGLQȝ/RIQXFOHDU-extraction reagent. 
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After a 40-min incubation period, with vortexing every 10 min and another centrifugation 
at 16,000g for 10 min, the supernatant (nuclear extract) was collected. Cytoplasmic and 
nuclear protein concentrations were measured by Bradford method as mentioned above. 
Extracts were aliquoted and stored at -80o C until the day of the determination.  
3.10 Apoptosis level  
Western blot was used to quantify the cytoplasmic caspase 3 and cleaved caspase 3 in the 
lung tissues in response to treatments. Briefly, samples (cytoplasmic extracts) were` 
adjusted to equal amounts of protein (50 ȝg protein/lane).  Proteins were run on 
electrophoresis (SDS-PAGE) gel. After electrophoresis proteins were transferred (90 V, 2 
hours, 4ºC) to a 0.45-ȝm pore size polyvinylidene difluoride membrane (BioRad) in tris-
glycine transfer buffer. After transfer, the membrane was blocked in tris-buffered 
saline(TBS) containing 2.5% milk powder (Bio-Rad) for 1 h, then the membrane was 
incubated overnight at 4ºC with a 1:1000 dilution of polyclonal anti-rabbit caspase-3 (Cell 
Signaling Technology). Detection was performed by using horseradish peroxidase–
conjugated secondary anti-rabbit (Cell Signaling Technology) at a 1:2000 dilution, and the 
enhanced chemiluminescence reagent system (Femto, Pierce, U.S.A), using Kodak BioMax 
light film. To evaluate the levels of reference protein (alpha tubulin), the blots were 
stripped in Western-blot stripping buffer (Pierce) for 15 min, at room temperature. After 
being blocked in TBS containing 5% milk powder for 1 h at room temperature, the blots 
were incubated with a polyclonal mouse antihuman (US Biological) at a dilution 1:500, and 
with a secondary anti-mouse horseradish peroxidase-conjugated antibody (R&D Systems) 
at a dilution 1:2000, for 1 hour at room temperature, with detection as described above.
To quantitatively assess the amount of cleaved caspase-3 in the cytoplasm, the films were 
digitally imaged. The pixel intensity of each band determined, by using image analysis 
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software (UN-scan-it gel 6.1).  The activation of caspase-3 and cleaved caspase 3 were
calculated relative to tubulin [190].
3.11 Activation of Nrf2 
Western blot was used to quantify the cytoplasmic and nuclear Nrf2 in the lung tissues in 
response to treatments. Briefly, samples (cytoplasmic and nuclear extracts) were adjusted 
to equal amounts of protein (30 ȝg protein/lane).  Proteins samples were run on 
electrophoresis (SDS-PAGE) gel. After electrophoresis proteins were transferred (90 V, 2 
hours, 4ºC) to a 0.45-ȝm pore size polyvinylidene difluoride membrane (BioRad) in Tris-
glycine transfer buffer. After transfer, the membrane was blocked in phosphate-buffered 
saline (PBS) containing 5% milk powder (Bio-Rad) for 1 h, then the membrane was 
incubated overnight at 4ºC with a 1:1000 dilution of  anti-human Nrf2 monoclonal IgG 
(Novus Biological) . Detection was performed by using a secondary anti-rabbit horseradish 
peroxidase-conjugated antibody (Cell Signaling Technology) at 1:2000, for 1 hour at 23ºC, 
followed by the enhanced chemiluminescence reagent system (Plus-ECL,PerkinElmer, 
U.S.A ), using Kodak BioMax light film.  To evaluate the levels of nuclear protein in the 
nuclear extracts, the blots with nuclear extracts were incubated with anti-human Nrf2 
monoclonal IgG (Novus Biological) at a 1:1000 dilution, and with a secondary anti-rabbit 
horseradish peroxidase-conjugated antibody (Cell Signaling Technology) at 1:2000, for 1 
hour  at 23ºC [191], with detection as described above.
To evaluate the levels of reference protein (alpha tubulin), the blots were incubated with a 
polyclonal mouse antihuman (US Biological) at a 1:500 dilution, and with a secondary anti-
mouse horseradish peroxidase-conjugated antibody (R&D Systems ) at  a dilution  1:2000, 
for 1 hour  at 23ºC, with detection as described above .
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To quantitatively assess the amount of Nrf2 in the cytoplasm and nucleus, the films were 
digitally imaged. The pixel intensity of each band determined, by using image analysis 
software (UN-scan-it gel 6.1).  The quantity of Nrf2 was determined relative to tubulin.
3.12 Activation of NFNB
Western blot was used to quantify the level of cytoplasmic and nuclear NFNB in lung 
tissues in response to treatments. Briefly, samples (cytoplasmic and nuclear extracts) were 
adjusted to equal amounts of protein (50 ȝg protein/lane).  Proteins were run on 
electrophoresis (SDS-PAGE) gel. After electrophoresis proteins were transferred (90 V, 2 
hours, 4ºC) to a 0.45-ȝm pore size polyvinylidene difluoride membrane (BioRad) in Tris-
glycine transfer buffer. After transfer, the membrane was blocked in PBS containing 5% 
milk powder (Bio-Rad) for 1 h, then the membrane was incubated overnight at 4ºC with a 
1:1000 dilution of  mouse polyclonal  NFNB antibody (MaxPab). Detection was performed 
by using a secondary anti-mouse horseradish peroxidase-conjugated antibody (R&D
Systems) at  a dilution  1:2000, for 1 hour  at 23ºC, following by the enhanced 
chemiluminescence reagent system (Plus-ECL, PerkinElmer, U.S.A), using Kodak BioMax 
light film.  To evaluate the levels of nuclear protein in the nuclear extracts, the same as 
described above.
To evaluate the levels of reference protein (alpha tubulin), the blots were incubated with a 
polyclonal mouse antihuman (US, Biological) at a dilution 1:500, and with a secondary 
anti-mouse horseradish peroxidase-conjugated antibody (R&D Systems) at  a dilution  
1:2000, for 1 hour  at 23ºC, with detection as described above.
To quantitatively assess the amount of NFNB in the cytoplasm and nucleus the films were 
digitally imaged. The pixel intensity of each band was determined, by using image analysis 
software (UN-scan-it gel 6.1).  The level of NFNB was determined relative to tubulin.
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3.13 Determination of Methionine adenosyl transferase 
Liver sample was homogenated on ice during 20 seconds with Polytron (Biospec Products, 
Bartlesville, OK, USA) in 4 volumes of (10 mM Tris/HCL, 0.3 M sucrose, 1 mM 
benzamidine, 0.1 mM phenylmethanesulfonylfluoride, and pH 7.5). The homogenate was 
centrifuged at 40000 g for 2h30 at 4 C°. The supernatants were taken for determination of 
MAT activity and protein level. The supernatants were incubated at 37C° for 30 min with 
(75m M Tris/HCL, 250 mM KCl, 9 mM MgCl2, 60 μM methionine and 5 mM [2-³H]ATP 
(1Ci/mol), pH 7.8). The reaction was stopped by adding 3 ml of cold water and 
immediately applied onto the cation exchanger Dowex AG5OW columns (0.5 ml) that was 
previously prepared and balanced with water, adjusted pH at 7 with NaOH. The 
chromatography was made at room temperature. Subsequently, the column was washed 
with 20 ml water to get rid of the unused radioactive substrate. The H3-S-adenosyl 
methionine was eluted by using 4 ml of 3M NH4OH. The radioactivity of this fraction was 
measured by liquid scintillation by a beta counter (Beckman Co, Fullerton, CA, USA). The 
activity was expressed as nmol-S-adenosyl methionine formed/min/mg protein at 37°C. 
[192, 193,194]
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Highlights
- Oxidative stress is suspected to induce bronchopulmonary dysplasia. 
- We investigate the role of ascorbylperoxide contaminating parenteral nutrition.
- This molecule induces oxidation of redox potential, apoptosis and loss of alveoli.
- The alveolar loss is independent of the redox potential. 
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In premature human newborns :
• Ĺ2[LGDWLYHVWUHVV
•Bronchopulmonary dysplasia
•ĹDOYHRODUhypoplasia is the main feature)
In newborn guinea pigs :
• Ĺ5HGR[SRWHQWLDO
• Ĺ%LRORJLFDOPDUNHUVRIR[LGDWLYHVWUHVV
(NFkB and Nrf2)
• Ø Apoptosis (cleaved caspase-3)
• Ø Alveolar number
In newborn guinea pigs :
• Ĺ5HGR[SRWHQWLDO
• Ø Biological markers of oxidative stress
(NFkB and Nrf2)
• Ĺ$SRSWRVLVFOHDYHGFDVSDVH-3)
• Ļ$OYHRODUQXPEHUindependent of redox potential)
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Abstract
Background: Bronchopulmonary dysplasia is one of the main complications associated 
with extreme prematurity. Oxidative stress is suspected to be a trigger event of this lung 
disease, which is characterized by impaired alveolar development. Peroxides, mainly 
ascorbylperoxide and H2O2, are known contaminant of parenteral nutrition. We hypothesize 
that these oxidant molecules induce bronchopulmonary dysplasia development. The aim 
was to determine if the infusion of ascorbylperoxide, whether in presence or absence of 
H2O2, is associated with oxidative stress, apoptosis and loss of alveoli in the lungs of 
newborn guinea pigs.
Method: Three days-old guinea pigs received parenteral solutions containing 0, 20, 60 or 
180 μM ascorbylperoxide in the presence or not of 350 μM H2O2 (concentrations similar to 
those measured in parenteral nutrition). After 4 days, the lungs were collected for 
determination of glutathione’s redox potential, caspase-3 activation (an apoptosis marker), 
alveolarization index (by histology), activation of Nrf2 and NFNB (biological markers of 
oxidative stress), and IL-6 & PGJ2 levels (markers of NFNB activation). Groups were 
compared by ANOVA, p < 0.05.
Results: Loss of alveoli was associated with ascorbylperoxyde in a dose-dependent manner, 
without an influence of H2O2. The dose-dependent activation of caspase-3 by 
ascorbylperoxide was lower in the presence of H2O2. Ascorbylperoxide induced an increase 
of redox potential in a dose-dependent manner, which reached a plateau in presence of 
H2O2. Nrf2 and NFNB were activated by H2O2 but not by ascorbylperoxide.
Conclusion: Results suggest that ascorbylperoxide, generated in parenteral nutrition, is 
involved in the development of bronchopulmonary dysplasia, independently of the increase 
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of the redox potential. This study underlines the importance of developing a safer 
formulation of parenteral nutrition. 
Key words: Premature newborn; oxidative stress; bronchopulmonary dysplasia; chronic 
lung disease; glutathione.
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Introduction
Decreased alveolar number and impaired vascular development are characteristic features 
of bronchopulmonary dysplasia (BPD) (1, 2). Extremely premature infants (<29 weeks of 
gestation) are affected by BPD in 50% of cases. Amongst the multiple consequences of 
BPD, lung function impairment, which can persist until adulthood (3-5), and altered 
neurodevelopment are the most worrisome (6, 7).  Requirement in oxygen supplementation, 
with its associated oxidative stress, has long been recognized as a component in the 
aetiology of BPD (1, 2, 8). Recently, parenteral nutrition (PN) has been suggested to play 
an important role in BPD development. It has been reported that peroxides, which 
contaminate PN, induce oxidative stress in newborn animals (9) as well as in premature 
infants (10). Light-protection of PN reduces by half the peroxide generation in intravenous 
solution (10-12), decreases the incidence of BPD (13) and chronic lung diseases (12) in 
premature infants and prevents the alveolar loss in newborn guinea pigs (14). An animal 
study by Lavoie JC et al. (15) reported that an exaggerated apoptosis is associated with the 
loss of alveoli, independently of the H2O2 level present in PN. This study also described 
that the loss of alveoli is reproduced by the infusion of a solution containing vitamin C and 
riboflavin, components found in PN. Interaction between these two vitamins, in presence of 
ambient light, generates a new organic peroxide derived from the peroxidation of 
dehydroascorbate by H2O2 (16, 17). We suspect that this molecule (2,3-diketo-4-
hydroxyperoxyl-5,6-dihydroxyhexanoic acid), named in the current report as 
“ascorbylperoxide”, participates in the development of BPD. 
Peroxides are detoxified by the glutathione metabolism, in which GSH is oxidized into 
GSSG. The concentration of both forms of glutathione impacts on the cellular redox 
environment. Because cell cycle (proliferation, differentiation and apoptosis) is influenced 
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by the redox environment (18), the presence of peroxides in PN can induce arrest of 
pulmonary development or even apoptosis. Chessex et al. (19) have recently reported that 
the level of redox potential of glutathione measured in blood of premature infants was 
strongly correlated with the severity of BPD (19). We hypothesize that ascorbylperoxide 
infused with PN induces oxidative stress characterized by a higher redox potential, which 
stimulates apoptosis and leads to alveolar loss. Therefore, the aim of this study was to 
document that the infusion of increasing concentrations of ascorbylperoxide is associated 
with an elevation of redox potential of glutathione, activation of an apoptosis marker and a 
reduced number of alveoli in the lungs of newborn guinea pigs Because PN contains also 
H2O2, which can potentially exacerbate the oxidation of glutathione, the intravenous
solutions infused to animals in this study will contain or not H2O2 (ascorbylperoxide r
H2O2). 
Materials and Methods
Sixty Hartley guinea pigs (Charles River Laboratories, Saint-Constant, Quebec, Canada) 
have been used in eight groups (6-9 animals per group). At three days of life, a catheter 
(SAI Infusion Technologies, Lake Villa, IL) was fixed in the right jugular vein as 
previously described (13, 14, 20) to inject the experimental intravenous solutions freshly 
prepared each day. The solutions, which were continuously infused at a rate of 19 
mL/100g/d (21), contained:  8.7% (w,v) dextrose + 0.3% (w,v) NaCl + 1 U/mL heparin + 
0, 20, 60 or 180 μM ascorbylperoxide ± 350 μM H2O2 (concentrations previously 
measured in total parenteral nutrition) (11, 14). A usual total parenteral nutrition containing 
1% of a multivitamin preparation (Multi-12 pediatric, Sandoz, Boucherville, QC, Canada) 
generates 36 ± 1 μM ascorbylperoxide (J.C. Lavoie, personal communication). Because 
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ascorbylperoxide does not commercially exist, it was generated in vitro, as previously 
described (21). After 4 days, lungs were collected as per the protocol previously explained 
in (14) and (15). The right lung was used for biochemical measurements and the left one 
was used for histology. Urine was collected directly from the bladder for determination of 
ascorbylperoxide concentration. Forty-eight animals had urine in their bladder at the time 
of sacrifice. The protocols were approved by the Institutional Committee for Good Practice 
with Animals in Research, in accordance with the Canadian Council of Animal Care 
guidelines.
Alveolarization index represents the mean value for each animal of the number of intercepts 
between a standardized straight-line (1 mm) and histological structures calculated from 
four different fields of the same lung (200X magnification) (14, 15).
Ascorbylperoxide concentration in intravenous solutions, as well as in urine, was quantified 
by using a LC/MS methodology previously described (16, 21). Because the internal 
standard was L-2-oxothiazolidine-4-carboxylate (OTC), results are expressed in OTC 
equivalent. 
Glutathione (GSH and GSSG) was determined by capillary electrophoresis, as previously 
described (20-22), whereas the redox potential was calculated (25ºC, pH 7) by using the 
Nernst equation.
Apoptosis was defined by calculating the proportion of active (cleaved caspase-3) on total 
caspase-3 (cleaved + non-cleaved). These two forms of the protein were quantified by 
Western blot as described in (22).
Nrf2 and NFNB: In order to qualify the oxidative stress, in addition to glutathione redox 
state, protein levels of Nrf2 and NFNB have also been measured. Nrf2 is a nuclear factor 
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involving antioxidant defences. It favours the transcription of genes encoding for, among
others, glutathione synthesis. NFNB is a nuclear factor favouring inflammation. 
Determination by Western blot (23) of their cytosolic level and nuclear fraction, using a 
commercially nuclear and cytoplasmic extraction kit (Pierce Biotechnology, Rockford, IL, 
USA), allowed calculation of the proportion present in the nucleus (active form). They 
were reported as activated protein (nuclear level / nuclear + cytosolic levels). The Western 
blot method described by Hübner RH et al. (23) was used, except for the antibody against 
NFNB, for which we have used the MaxPab mouse polyclonal NFNB antibody from 
Abnova (Taipei, Taiwan). 
IL-6 and PGJ2:  From lung homogenate (1 in 4 volume of water), concentration of IL-6
was evaluated by the Human IL-6 ELISA kit (Anogen Mississauga, Ontario) whereas the 
15-deoxy-ǻ12,14-PGJ2 EIA kit (Enzo, Plymouth, PA, USA) was used to measure PGJ2
levels after a C-18 extraction (24). 
Statistical analysis: Data from each group are presented as mean ± s.e.m, and have been 
compared by factorial ANOVA (4 concentrations of ascorbylperoxide x H2O2). All 
comparisons were orthogonal. To meet the homoscedasticity, which was verified by using 
the Bartlett’s Chi squared test, data for GSH, Nfr2 and NFNB have been logarithmically 
transformed. The level of significance was set at p-value < 0.05. Comparison between 
groups receiving the solutions devoid of ascorbylperoxide and groups infused with the 
three concentrations of this peroxide was used to statistically document the effect of 
ascorbylperoxide. The use of coefficients for linear and quadratic polynomials allowed 
analysis of the dose-response effect of ascorbylperoxide. A significant interaction between 
H2O2 and ascorbylperoxide led us to analyse the impact of ascorbylperoxide separately of 
the presence or absence of H2O2.
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Results 
There was no statistical difference between initial mean body weight among groups (104 r
2 g (n=60); H2O2 effect: F(1,52) < 0.1; ascorbylperoxide effect: F(3,52) =1.3). The urinary 
concentration of ascorbylperoxide (Figure 1) increased (F(1,40)= 12.6, p<0.01) linearly 
(F(1,40)= 37,3, p<0.01) in function of the dose of ascorbylperoxide received and was 25% 
lower in animals infused with solutions containing H2O2 (F(1,40)= 5.9, p<0.05). The total 
amount of intravenous solution received was similar (F(1,40)= 0.3) in the group receiving 
H2O2 (72.3 r 1.3 mL) and in the group without H2O2 (71.9 r 0.8 mL) .
The ANOVA revealed a significant interaction between ascorbylperoxide and H2O2 (F(3,49)
=3.1, p<0.05) on the redox potential of glutathione in the lungs (Figure 2A). In the absence 
of H2O2, the ascorbylperoxide has induced an increase of the redox potential (F(1,49) =7.7, 
p<0.01) that was linearly dependent on the dose (F(1,49) =4.4 p<0.05), whereas in presence 
of H2O2 the redox potentials were not influenced by ascorbylperoxide (F(3,49) = 0.7). The 
mean value of redox in H2O2 groups was of -203 ± 1 mV (n = 28). This value was similar 
to the one measured in the groups 60 and 180 PM ascorbylperoxide without H2O2. The 
modification in redox potential was caused by modification in GSH rather than a change in 
GSSG value. Indeed, there was no modification in GSSG levels between groups (0.61 ± 
0.03 nmol/mg prot, n= 57) whereas a significant interaction (F(1,49) = 4.0 p<0.05) between 
ascorbylperoxyde and H2O2 was observed for GSH values (Figure 2B). The level of GSH 
was lower in the lung of animals infused with a solution containing ascorbylperoxide or 
H2O2. The actions of these peroxides were not additive (significant interaction) and the 
effect of ascorbylperoxide was not dose-dependent (F(1,49) < 2.1) (Figure 2B).
Ascorbylperoxide and H2O2 influenced the levels of activated caspase-3 (Figure 3). The 
absence of significant interaction (F(3,52) = 1.0) suggested an additive effect. In fact, data 
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show that ascorbylperoxide was a linear dose- dependent (F(1,53) = 5.3, p < 0.05) inducer 
(F(1,53) = 24.7, p < 0.01), whereas H2O2 had a 15% inhibitory effect (F(1,53) = 11.3, p < 0.01). 
The activated caspase-3 is defined as the ratio of cleaved caspase-3 on the total caspase-3
(cleaved + non-cleaved) (Figure 4). Ascorbylperoxide (p < 0.01) and H2O2 (p < 0.05) had a 
similar impact on cleaved caspase-3 and on activated caspase-3 whereas they did not 
influence the level of the non-cleaved enzyme. The low level of non-cleaved caspase-3 in 
the group 180 PM ascorbylperoxide without H2O2 remains without explanation. 
Despite the negative impact of H2O2 on the apoptosis marker (Figure 3), the alveolarization 
index (Figure 5A) was influenced only by ascorbylperoxide (F(1,47) = 6.8, p < 0.05), not by 
H2O2 (F(1,47) = 0.1), without interaction (F(3,47) = 0.6). The decreasing in alveolarization 
index responded to a linear dose-effect of ascorbylperoxide (F(1,47) = 9.0, p<0.01). 
Examples of histology of lungs are shown on the Figure 5B.
Due to the difference in effect between both peroxides on alveolarization index, a doubt 
persisted on the value of the observed redox potentials and on the real oxidative capacity of 
each peroxide infused during the four days of the experiment. Thus, biological markers of 
oxidative stress, such as NFNB and Nrf2, were measured. Both peroxides were associated 
with a similar impact on activated NFNB and Nrf2 (Figure 6A and 6B, respectively). Their 
levels were higher in animals receiving H2O2 (F(1,49) = 14.9, p < 0.01) and ascorbylperoxide
(F(1,49) = 8.2, p < 0.01), without a dose-effect (F(1,49) = 1.0). The interactions did not reach 
statistical significance (F(3,49)= 1.8). 
Examples (n = 3 for each group) of Western blot of proteins measured in cytosolic and 
nuclear fractions are shown in Figure 7. Complete values are reported in Figures 8 and 9.
NFNB levels in nucleus (Figure 8A) and in cytosol (Figure 8B) were higher in animals 
infused with solutions containing ascorbylperoxide (F(1,49)= 4.9, p < 0.05), independently of 
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the presence of H2O2 (no interaction, F(3,49) = 2.8). The effect of ascorbylperoxide was 
without dose-effect (F(1,49)=2.0). NFNB was lower in the cytosolic fractions of lungs from 
animals infused with solution containing H2O2 (F(1,49) =23.1, p < 0.01). H2O2 had no effect 
on values in nucleus (F(1,49) = 1.5). 
In the nucleus, the interaction between peroxides for Nrf2 was significant (F(3,49) = 3.0, p < 
0.05) (Figure 9A). The levels of Nrf2 were higher in animals receiving solutions 
containing both peroxides (F(1,49) = 9.1, p < 0.01) without dose-effect of ascorbylperoxide 
(F(1,49) = 3.9). Without H2O2, ascorbylperoxide was without significant effect (F(1,49) = 1.6). 
In the cytosol, the levels of Nrf2 were lower in animals infused with solutions containing 
H2O2 (F(1,49) = 4.5, p < 0.05), whereas ascorbylperoxide was without significant effect on 
Nrf2 levels (F(1,49) = 2.0). There was no interaction between H2O2 and ascorbylperoxide on 
the cytosolic Nrf2 levels (F(3,49) = 0.9).
The efficiency of activation of NFNB by peroxides was evaluated by measuring two 
molecules derived from his activation. The four-day exposure to the peroxides could induce 
inflammation. Thus, IL-6 level (a pro-inflammatory marker) was measured, as well as and 
PGJ2 level (an anti-inflammatory marker). There was no significant effect on IL-6 (mean r
sem = 0.69 r 0.06 pg/mg prot; F(1,20) < 3.9), whereas PGJ2 levels (Figure 10) were higher 
in the H2O2 groups (F(1,51) = 9.4, p < 0.01). Ascorbylperoxide was without significant effect 
(F(1,51) = 0.02) on PGJ2 level. There was no significant interaction (F(1,51) = 0.3). 
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Discussion
This study highlights the toxic effect of ascorbylperoxide, a by-product of peroxidation of 
dehydroascorbate generated in the solution of parenteral nutrition, on the lungs of our 
animal model.  After four days of infusion, this molecule has induced one of the main 
features of BPD (a lower alveoli number), independently of the presence of H2O2.
Consistent with our hypothesis, this study demonstrated that ascorbylperoxide has 
produced 1) an oxidation of the redox potential, 2) an activation of caspase-3, a marker of 
apoptosis, and 3) a lower alveolarization index. The second part of the hypothesis was that 
H2O2, a contaminant of parenteral nutrition, exacerbates the oxidative stress and, 
consequently, influences the impact of ascorbylperoxide. Indeed, H2O2 has induced an 
oxidation of the redox potential that has reached a plateau. The mean redox value measured 
in animal infused with solutions containing H2O2 was similar to that observed in animals 
infused with solutions containing the two greatest concentrations of ascorbylperoxide 
(without H2O2). This observation suggests that the redox potential might not be the main 
trigger of the apoptosis. Indeed, although the animals infused with H2O2 had the highest 
redox potential, independently of the presence of ascorbylperoxide, the activation of 
caspase-3 by ascorbylperoxide was lower by 15% in H2O2 groups. Despite this negative 
effect of H2O2 on caspase-3, the activation remained sufficient to induce a decrease in the 
alveolar number. The effect of ascorbylperoxide on alveolarization index was similar to the 
values previously reported in studies investigating the effect of parenteral nutrition (14, 
15).The discrepancy between redox potential values and activation of caspase-3, especially 
in H2O2 groups, suggests that the modification of the redox potential could be not enough to 
induce biologically pertinent oxidative stress. The study of the impact of both peroxides on
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the activation of NFNB and Nrf2 is instructive.  The effects of ascorbylperoxide on redox 
potential, caspase-3 and alveolarization index were linearly dependent to the dose infused. 
In contrast, the positive impact of this peroxide on activation of NFNB and Nrf2 is not 
dose-dependant and reached a plateau at the lowest concentration. The levels of NFNB in 
cytosol and nucleus also reached a plateau, whereas no activation of Nrf2 by 
ascorbylperoxide was documented in cytosol and nucleus. One may question the relevance 
of the activation of NFNB by ascorbylperoxide considering the absence of dose-effect 
between those two molecules. Indeed, levels of IL-6 and PGJ2, two products of this 
activation, were not affected by ascorbylperoxide. Thus, the biological oxidative capacity 
of infused ascorbylperoxide in lungs is limited. In addition, the action of ascorbylperoxide 
on redox potential of glutathione is linked to a lower level of GSH rather than elevation of 
GSSG, an oxidized form of glutathione. 
The statistically significant effect of H2O2 on activation of NFNB resulted from a lower 
level of NFNB in the cytosol rather than from a higher level in the nucleus. However, the 
activation is suggested by the positive impact of H2O2 on PGJ2 levels. Thus, in contrast to 
ascorbylperoxide, the oxidative effect of infused H2O2 is confirmed by the activation of 
NFNB, the increase of PGJ2 and the activation of Nrf2. The similarity between the 
histogram of nuclear Nrf2, shown in Figure 9A, and the results for PGJ2 level (Figure 10)
suggest that the activation of Nrf2 in H2O2 groups is induced by PGJ2 (25) rather than by 
the direct oxidative property of H2O2. Thus, independently of its effects on the redox 
potential of glutathione, ascorbylperoxide seemed to be without biological oxidative 
capacity in the lungs. Ascorbylperoxide has induced alveolar loss following activation of 
caspase-3. H2O2 exerted a biological oxidative stress, but without an effect on 
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alveolarization index. Those results put into question the relation between oxidative stress 
and the effect of PN on BPD
From a previous report by our group, it is known that H2O2 infused with parenteral nutrition 
inhibits the hepatic pathway of transformation of methionine into cysteine, of which the 
availability is a rate-limiting step in the glutathione synthesis (20). This is in accordance 
with the current study in which the increase of redox potential of glutathione was related to 
a lower GSH rather than to a higher GSSG. The inhibition of hepatic transformation of 
methionine by PN containing H2O2 led to a lower glutathione concentration in liver and in 
blood (20). Glutathione in blood circulation is an important source of substrates for the de 
novo cellular synthesis of GSH. Indeed, by-SURGXFWVRIWKHȖ-glutamyltranspeptidase action 
on the glutathione that is in blood circulation are captured by the cell and are processed to a 
new synthesis of glutathione. A similar inhibition by ascorbylperoxide could also explain 
the lower level of GSH in lungs from animal infused with ascorbylperoxide alone.  
The discrepancy between the positive effect of H2O2 on Nrf2 and its negative effect 
(increase) on redox potential is surprising. Nrf2 is well known to be the nuclear factor that 
favours a new synthesis of GSH (26). The absence of concordance between them could be 
explained by a limiting availability of substrate, specifically cysteine, for the de novo
synthesis of glutathione. The experimental design involved the use of a solution containing 
only ascorbylperoxide r H2O2, without amino acids or lipids. However, glucose was the 
only carbon substrate added as an energy source. The levels of glutathione in animals 
infused with these solutions, which were devoid of substrates for GSH synthesis, ranged 
from 21 to 33 nmol/mg prot (Figure 2). These levels were similar (16 to 23 nmol/mg prot) 
to those reported in a previous study where animals received total parenteral nutrition that
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included amino acids (14). Thus, in the present study, the GSH pool seems in equilibrium. 
Lack of amino acids in nutrition of animals may still limit the de novo protein synthesis 
following gene transcription. 
The association between the redox potential of glutathione (measured in lungs from 
animals infused with solutions containing ascorbylperoxide) and the alveolarization index 
is in accordance with the association reported by Chessex et al. (19). Indeed, the 
aforementioned study described a relationship between the severity of BPD and the redox 
potential of glutathione measured in whole blood of premature newborns. However, our 
results suggest that these two parameters are parallel events rather than being 
interconnected. The discrepancy between pulmonary redox potential and alveolar count has 
already been reported in newborn guinea pigs infused with parenteral nutrition, despite 
presence or absence of photo-protection (14).
Activation of caspase-3 leads to cleavage of cellular proteins, a process of irreversible 
apoptosis (27). This protease is activated by caspase-8, caspase-9 or caspase-10. Following 
impairment of mitochondria, cytochrome c is released and transforms the pro-caspase-9 in 
an active protease (28). Caspases-8 and 10 are activated following stimulation of receptors 
such as Fas receptor or Tumour necrosis factor receptor 1 (29). The redox potential does 
not seem to play a key role in the activation of caspase-3 and H2O2 reduces the activation 
of caspase-3. These observations suggest that ascorbylperoxide effect on caspase-3 is 
through the death receptors (29). From activation of these receptors until the final endpoint 
of apoptosis: caspase-8 is firstly activated, followed by the activation of caspase-3 by 
caspase-8. The fact that the later is inhibited by H2O2 (30) might explain the negative effect 
of H2O2 on caspase-3 activation, as found in our animal model. 
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Levels of ascorbylperoxide in urine were lower in animals infused with solutions 
containing H2O2. These animals received intravenous solutions in similar amount to the 
ones who were infused with solutions devoid of H2O2. These findings suggest that animals 
receiving solutions containing H2O2 had a better capacity to detoxify ascorbylperoxide and 
that the concentration of ascorbylperoxide is important for the activation of caspase-3. The 
detoxification of ascorbylperoxide could be due to a higher activity of glutathione S-
transferases, secondary to the greater activation of Nrf2 in the H2O2 group. Further studies 
are needed to clarify the interactions between ascorbylperoxide, Nrf2 activation, 
glutathione S-transferases and their effects on alveolar loss. 
Ascorbylperoxide is considered a xenobiotic due to its in vitro formation (in the parenteral 
nutrition solution) (17). However, in animals infused with a solution devoid of 
ascorbylperoxide but containing H2O2, the level of ascorbylperoxide is measurable in the 
urine (Figure 1). This could be explained by the interaction between H2O2 and 
dehydroascorbate, elements that are both present in the urine and are known to be precursor 
of ascorbylperoxide production (16). The relation between the urinary concentrations of 
ascorbylperoxide in function of the quantity infused could be useful for a further clinical 
investigation on the impact of ascorbylperoxide on BPD development.
Conclusion
Ascorbylperoxide generated in parenteral nutrition appears to be related to the loss of 
alveoli associated to apoptosis induction. Although this molecule induces an increase of the 
redox potential, findings of the current study suggest that this is a parallel phenomenon to 
apoptosis. Indeed, the shift in the redox potential toward a more oxidized status, as 
observed with ascorbylperoxide and with H2O2, is perhaps not sufficient to induce 
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apoptosis (18). However, this modification of the redox value should not be taken lightly. 
The increase of the redox potential obtained with ascorbylperoxide or H2O2 could influence 
the proliferation and the differentiation of cells (18). Pulmonary development, such as in 
premature newborns, must go through cellular proliferation, differentiation and apoptosis 
for the remodelling of the lungs, until they reach their final maturity. Bronchopulmonary 
dysplasia may result from the perturbation of several of these cellular states. In our 
experimental model, we have exposed the association between the loss of alveoli, a feature 
of bronchopulmonary dysplasia, and ascorbylperoxide. The impact of ascorbylperoxide on 
other cellular stages and on the nature of the affected cells should be the focus of future 
investigations. Nevertheless, since the generation of ascorbylperoxide is dependent on light 
exposure (17), the present study supports the beneficial effect of photo-protection of 
parenteral nutrition on chronic lung disease (12), such as BPD (13) in neonates. Our results 
add an important piece of information regarding the mechanism by which parenteral 
nutrition, as presently compounded, can induce BPD development. 
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Legends for Figures
Figure 1: Influence of ascorbylperoxide and H2O2 on the urine concentration of 
ascorbylperoxide.
The level of ascorbylperoxide in urine increased (**: 0 vs. 20, 60,180 PM; p<0.01) linearly 
in function of the received dose of ascorbylperoxide (#: between 20, 60,180 PM; p<0.01) 
and was lower in groups infused with solutions containing H2O2 (with vs. without H2O2;
p<0.05).  Mean r s.e.m.; n = 4-7.
Figure 2:  Influence of ascorbylperoxide and H2O2 on the redox potential of 
glutathione and GSH level in lungs.
Due to the significant interaction (p<0.05) between ascorbylperoxide and H2O2, the effects 
of the ascorbylperoxide on the redox potential and on GSH have been analyzed according 
to the presence or not of H2O2. Panel A: In absence of H2O2, the redox potential was lower 
in the group devoid of ascorbylperoxide (**: 0 vs. 20, 60,180 PM; p<0.01). The impact of 
the ascorbylperoxide was linearly dose- dependent (#: between 20, 60,180 PM; p<0.05). 
There was no modification of redox potential by the ascorbylperoxide in animals infused 
with solution containing H2O2. Panel B: In absence of H2O2, the GSH level was higher in 
the group devoid of ascorbylperoxide (**: 0 vs. 20, 60,180 PM; p<0.01). The impact of the 
ascorbylperoxide was independent of the dose (no difference between 20, 60,180 PM). 
There was no modification of the GSH value in animals infused with solution containing 
H2O2. Mean r s.e.m.; n = 6-9.
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Figure 3:  Influence of ascorbylperoxide and H2O2 on the activated caspase-3.
The level of activated caspase-3 was increased (**: 0 vs. 20, 60,180 PM; p<0.01) linearly 
in function of the received dose of ascorbylperoxide (#: between 20, 60,180 PM; p<0.05) 
and was lower in groups infused with solutions containing H2O2 (with vs. without H2O2;
p<0.01).  Mean r s.e.m.; n = 4-7
Figure 4:  Influence of ascorbylperoxide and H2O2 on cleaved and non-cleaved 
caspase-3.
Panel A: Representative examples (n=3 per group) of Western blot obtained for the cleaved 
and non-cleaved caspase-3, relatively to tubulin. Panel B: The level of cleaved caspase-3
was lower in groups devoid of ascorbylperoxide (**: 0 vs. 20, 60,180 PM; p<0.01) but 
increased linearly in function of the dose of ascorbylperoxide (#: between 20, 60,180 PM; 
p<0.05). The level of cleaved caspase-3 was not affected by the presence of H2O2. Panel C: 
Non-cleaved caspase-3 was not affected by ascorbylperoxide or H2O2, with exception of 
the 180 PM ascorbylperoxide group (p<0.05). Mean r s.e.m.; n = 6-10.
Figure 5:  Influence of ascorbylperoxide and H2O2 on alveolarization index.
Panel A: The alveolarization index was higher in groups devoid of ascorbylperoxide (**: 0 
vs. 20, 60,180 PM; p<0.05). The impact of the ascorbylperoxide was linearly dose-
dependent (#: between 20, 60,180 PM ; p<0.01). The alveolarization index was not affected 
by the presence of H2O2. Panels B-E: Representative examples of histological pictures of 
lungs from animals infused with a solution (B) devoid of H2O2 and of ascorbylperoxide, 
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(C) containing 350 ȝM H2O2 without ascorbylperoxide, (D) containing 180 ȝM
ascorbylperoxide without H2O2, or (E) containing 350 ȝM H2O2 and 180 ȝM
ascorbylperoxide.  The alveolarization index is based on the number of histological 
structures crossing the calibrated (1 mm) line. Mean r s.e.m.; n = 6-10.
Figure 6:  Influence of ascorbylperoxide and H2O2 on the activated NFNB and Nrf2 in 
lungs.
Activation of NFkB (panel A) and of Nrf2 (panel B) were lower on groups without 
ascorbylperoxide (**: 0 vs. 20, 60,180 PM; p<0.01). However, the impact of 
ascorbylperoxide was without dose-effect (no difference between 20, 60,180 PM). There 
was an additive effect of H2O2 (p<0.01) on activation of both factors. Mean r s.e.m.; n = 6-
8.
Figure 7:  Representative examples of Western blot results for NFNB and Nrf2 
determined in cytosol and nucleus. 
Three examples of Western blot results (relative to tubulin) for each group of animals 
infused with 0 to 180 PM ascorbylperoxide r 350 PM H2O2 on the nuclear (Panel A) and 
cytosolic fraction (Panel B) of Nrf2 and NFkB in lungs. Full data are shown in figure 8. 
Figure 8:  Influence of ascorbylperoxide and H2O2 on nuclear and cytosolic NFNB.
Panel A: Nuclear levels of NFNB were lower on group without ascorbylperoxide (**: 0 vs. 
20, 60,180 PM; p<0.01). The impact of ascorbylperoxide was without dose-effect (no 
difference between 20, 60,180 PM). The presence of H2O2 had no impact on results. Panel 
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B: Cytosolic levels of NFNB were lower on group without ascorbylperoxide (*: 0 vs. 20, 
60,180 PM; p<0.05). The impact of ascorbylperoxide was without dose-effect (no 
difference between 20, 60,180 PM). Cytosolic levels of NFNB were lower in presence of 
H2O2 (p<0.01). Mean r s.e.m.; n = 6-10.
Figure 9:  Influence of ascorbylperoxide and H2O2 on nuclear and cytosolic Nrf2.
Panel A: Due to the significant interaction (p<0.05) between ascorbylperoxide and H2O2, 
the effects of the ascorbylperoxide on nuclear levels of Nrf2 have been analyzed according 
to the presence or not of H2O2. In absence of H2O2, there was no difference between 
groups. In presence of H2O2, the nuclear level of Nrf2 was lower in the group devoid of 
ascorbylperoxide (**: 0 vs. 20, 60,180 PM; p<0.01). Panel B: Ascorbylperoxide was 
without effect on cytosolic Nrf2 levels whereas they were lower in animals infused with 
solutions containing H2O2 (p<0.05). Mean r s.e.m.; n = 6-10.
Figure 10:  Influence of ascorbylperoxide and H2O2 on PGJ2.
Ascorbylperoxide was without effect on PGJ2 levels whereas they were higher in animals 
infused with solutions containing H2O2 (p<0.01). Mean r s.e.m.; n = 6-10.
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Highlights 
1- Methionine adenosyltransferase (MAT) is essential for healthy liver.
2- Parenteral nutrition (PN) inhibits hepatic MAT.
3- The inhibition is caused by intrinsic peroxides and by unknown component of PN.
4- Adding glutathione in PN is not sufficient to prevent PN-associated liver diseases.
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CONTEXT  
Liver disorders associated with PN (parenteral nutrition).
Importance of MAT (methionine adenosyltransferase) for the hepatic health.
RESULTS
In newborn guinea pigs, PN inhibits MAT activity by a double mechanisms:
1) by intrinsic peroxides (contaminating) of PN that oxidize
i) thiol functions of MAT leading to its inhibition, and
ii) redox potential of glutathione, limiting the recycling of oxidized MAT
2) by an unknown component of PN that inhibits MAT by a peroxide independent mechanism.
MAT-SH MAT-SOH+  H2O2
MAT-S-SG
GSHGrx
Redox 
potential
Grx: glutaredoxin. GSH: reduced glutathione
CONCLUSION
Correction of redox potential by adding glutathione in PN 
is not enough to restore MAT activity
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Abstract
Background & Aims: The oxidation of the methionine adenosyltransferase (MAT) by the 
combined impact of peroxides contaminating parenteral nutrition (PN) and oxidized redox 
potential of glutathione is suspected to explain its inhibition observed in animals. A 
modification of MAT activity is suspected to be at origin of the PN-associated liver disease 
as observed in newborns. We hypothesized that the correction of redox potential of 
glutathione by adding glutathione in PN protects the MAT activity. Aim: to investigate 
whether the addition of glutathione to PN can reverse the inhibition of MAT observed in 
animal on PN.
Methods: Three days old guinea pigs received through a jugular vein catheter 2 series of 
solutions. First with methionine supplement, 1) Sham (no infusion); 2) PN: amino acids, 
dextrose, lipids and vitamins; 3) PN-GSSG: PN+10 PM GSSG. Second without 
methionine, 4) D: dextrose; 5) D+180 PM ascorbylperoxide; 6) D+350 PM H2O2. Four 
days later, liver was sampled for determination of redox potential of glutathione and MAT 
activity in presence or not of 1 mM DTT. Data were compared by ANOVA, p<0.05.  
Results: MAT activity was 45r4% lower in animal infused with PN and 23r7% with 
peroxides generated in PN. The inhibition by peroxides was associated with oxidized redox 
potential and was reversible by DTT. Correction of redox potential (PN+GSSG) or DTT 
was without effect on the inhibition of MAT by PN. The slope of the linear relation 
between MAT activity and redox potential was two fold lower in animal infused with PN 
than in others groups.
Conclusion: The present study suggests that prevention of peroxide generation in PN 
and/or correction of the redox potential by adding glutathione in PN are not sufficient, at 
least in newborn guinea pigs, to restore normal MAT activity.
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Key words: Parenteral nutrition; Peroxide; Newborn; Methionine adenosyltransferase; 
Thiol oxidation; Redox potential of glutathione.
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Introduction 
The intravenous nutritional support for individuals who have impaired or immature
gastrointestinal tract such as extreme premature infants is essential for their development
and health. However, several hepatic complications are associated with this mode of 
nutrition. In adults, parenteral nutrition (PN) induces hepatic steatosis (1,2) whereas the 
intra-hepatic cholestasis is frequent in premature infants (3,4). Animal data suggest that 
peroxides, H2O2 and ascorbylperoxide (2,3-diketo-4-hydroxyperoxyl-5,6-
dihydroxyhexanoic acid), that contaminating parenteral nutrition (5,6) are involved in these 
disorders (7,8). Peroxides can lead to perturbation of the metabolism following oxidation of 
the redox-sensitive thiol functions of specific proteins (Figure 1). Hence, the activity of the 
hepatic methionine adenosyltransferase (MAT) is inhibited by PN or infused H2O2 (9). 
MAT is at the crossroads of several metabolic pathways (Figure 1). For instance, MAT 
catalyzes the formation of S-adenosylmethionine, the main methyl donor of the organism 
(10,11). Perturbation in the generation of S-adenosylmethionine is frequently associated 
with hepatic disorders such as intrahepatic cholestasis (12,13). The activity of MAT is the 
first step in the transformation of methionine into cysteine of which the availability is a 
limiting step for glutathione synthesis (14). Intracellular concentration of GSH affects the 
activity of glutathione peroxidase during detoxification of peroxides (17). Thus, peroxides 
generated in the PN can induce a vicious cycle by inhibiting MAT that leads to a lower 
GSH (9), and therefore to a lower capacity to detoxify the infused peroxides. 
The oxidation of thiol into sulfenic acid (MAT-SOH) by peroxide is reversible (15). The 
mixed disulfide (MAT-SSG) formed following interaction of MAT-SOH with GSH is 
recycled into the native protein by the glutaredoxin using glutathione as electron donor. We 
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expect that the inhibition of MAT by PN occurs by this mechanism. The influence of the 
redox potential in the regeneration of MAT-SH, from MAT-SSG, is explained by its 
participation in the Gibbs equation (16) explaining a better efficiency of glutaredoxin in a 
more reduced environment.
Recently we have reported that addition of glutathione into PN led to a more reduced status 
of redox potential in lungs of newborn guinea pigs (17). We hypothesize that the addition 
of glutathione in PN will decrease the redox potential value (to a more reduced status) in
the liver, and consequently, will improve the regeneration of MAT activity. Therefore, the 
objectives of the study were 1) to compare the redox potential values as well as the hepatic 
MAT activities in newborn guinea pigs receiving a PN enriched or not with glutathione, or 
intravenous solutions containing peroxides, 2) to assess that the inhibition is caused by 
oxidation of thiols by using dithiothreitol (DTT), and 3) to document the relation between 
the redox potential and the activity of MAT. 
Methods
Animal model
At three days of life, Hartley guinea pigs (Charles River Laboratories, St-Constant, QC,
Canada) were anaesthetized by using ketamine and xylazine in order to fix a jugular 
catheter (Lake Villa, IL, USA). The catheter was placed and externalized in the scapular 
region, and connected to the infusion system. The studied solutions were infused 
continuously through the catheter at rate of 22 mL / 100 g body weight / d. The solutions 
were changed daily.
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Experimental designs 
We examined the stability of both GSH and GSSG in parenteral nutrition solution to decide 
which molecule should be used in further experiments. In plasma, J-glutamyltranspeptidase 
uses GSSG and GSH with the same efficiency to enrich the tissues into cysteine (essential 
for the cellular synthesis of GSH) (17,18). Twenty μM GSH or 10 μM GSSG (20 μM GSH 
equivalent) were added to PN (without lipid). After 1, 3, 5 and 24 hours incubation at room 
temperature, samples were collected for the determination of total glutathione 
(GSH+GSSG) using a colorimetric method (19) as previously described (17).
Based on the report documenting that diets with different intakes in methionine influence 
the activity of MAT (20), two different protocols were used to assess the impact of PN or 
peroxides on the MAT activity and on redox potential. For the first protocol three groups of 
animals, in which methionine was included in the nutrition, were compared:
1- Sham: The catheter was closed and animals were fed the regular laboratory food for 
Guinea pigs. 
2- PN: Animal were exclusively on intravenous solution containing 2% (w,v) amino acids 
(Primene, Baxter, Toronto, ON, Canada) 8,7% (w,v) dextrose, 1% (v,v) multivitamin 
preparation (Multi-12/K1 pediatrics, Sandoz, Boucherville, QC, Canada), 1.6% (w,v) 
lipid emulsion (Intralipid20%, Fresenius Kabi, Mississauga, ON, Canada) and 1 U/mL 
heparin . 
3- PN +10 μM GSSG: Animals were exclusively on PN containing 10 μM GSSG. This 
form of glutathione was choice to avoid interactions with other components of PN (17).
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For the second protocol three other groups of animals were compared. In order to isolate 
the effect of peroxides, the only carbon source for energy was dextrose (no amino acids or 
lipids):
4- D: Animals were infused with a solution containing 8.7% (w,v) dextrose, 0.3% (w,v) 
NaCl and 1 U/mL heparin.
5- AscOOH: Animals were infused with D containing 180 μM ascorbylperoxide; a 
concentration inducing perturbation of hepatic lipid and glucose metabolism (8) as well 
as redox potential in liver (8) and in lung (21) of newborn guinea pigs. 
6- H2O2: Animals were infused with D containing 350 μM H2O2; similar concentration of 
peroxides reported as contaminant in PN (21).
Four days later, at seven days of age, all animals were sacrificed. The liver samples were 
removed, processed and stored at -80°C until biochemical determinations.
In accordance with the principles of the Canadian Council, the Institutional committee for 
good practice with animals in research of CHU Sainte-Justine approved the present 
protocol. 
Determinations of redox potential of glutathione:
Briefly, as previously described (9,21), 0.5 g of liver was mixed with 5 volumes of 5% 
(w/v) freshly prepared metaphosphoric acid and homogenized on ice during 20 seconds 
with Polytron (Biospec Products, Bartlesville, OK, USA). After centrifugation 3 min at 
10000 RPM, supernatants were isolated for glutathione determination and pellets were used 
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for protein measurement. GSH and GSSG were separated by capillary electrophoresis
(Beckman Coulter). Assuming a density of 1.0 for the liver, the redox potential was 
calculated (25ºC, pH 7) by using the Nernst equation.
Determination of MAT activity: 
The activity of MAT was quantified on the cytosolic fraction of liver as previously 
described (9). Briefly, 300  ŨġŰŧġ űųŰŵŦŪůġ ĩŮŦŢŴŶųŦťwith BSA as 
standard) were suspended in the buffer (75 mM Tris/HCL, 250 mM KCl, 9 mM MgCl2, pH 
7.8) that contained substrates (5 mM methionine + 5 mM [2,8-³H]ATP (1Ci/mol)) for a
final volume of 150 μl , and were incubated 30 min at 37°C. To validate whether the 
inhibition of MAT was caused by oxidation of thiol functions of the protein, the buffer used 
for livers from Sham, PN and H2O2 groups contained or not, 1 mM dithiothreitol (DTT).  
Immediately after stopping the reaction by adding 3 ml of ice water, the total 3.15 ml were 
applied onto a 0.5 ml Dowex AG5OW column (BioRad laboratories). The column was 
treated with 20 ml water followed by 4 ml of 3M NH4OH to displace the tritiated S-
adenosylmethionine. The activity was calculated and expressed as nmol S-
adenosylmethionine formed/min/mg protein. 
Statistical analysis 
Results were expressed as mean r S.E.M. and were orthogonally compared by ANOVA 
after verification of the homogeneity of the variances by the Bartlett’s Chi squared. Paired 
ANOVA was used to analyse the impact of DTT on the MAT activity. The Pearson’s 
correlations between MAT activity and redox potential value were reported. The 
significance of the difference was set at p <0.05.  
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Results 
The stability of glutathione in PN (Figure 2) differed according to its redox form. After 3 
hours incubation the concentration of GSH was 50 ± 2% of the initial value whereas it 
remained 82±1% of GSSG. After 24 hours, it was 11± 2% of GSH and 72±2% of GSSG.
The initial body weights (108± 1.7 g n=43) as well as the relative liver weights (3.5r 0.1
g/100 g body weight) were similar between groups.
Compared to the Sham group, MAT activity (Figure 3A) was lower (p < 0.01) in groups 
that received PN or PN+GSSG. There was no difference (F(1,17)=1.1) between PN and 
PN+GSSG groups. Compared to the Control group (D), the MAT activity was lower (p < 
0.01) in groups that received H2O2 or ascorbylperoxide. There was no difference 
(F(1,18)=0.3) between H2O2 or ascorbylperoxide groups. The presence of DTT (Figure 4) in 
assay has increased the activity of MAT only in the H2O2 group. DTT was without effect in 
the Sham (F(1,14)=1.4) and PN (F(1,14)=2.2) groups. 
The redox potential of glutathione (Figure 3B) was lower (p < 0.01) in PN+GSSG group 
compared to the Sham group and PN groups. There was no difference (F(1,15)=0.4) between 
Sham and PN groups. Compared to the Control group (D), redox potential of glutathione 
was higher (p < 0.01) in groups that received H2O2 or ascorbylperoxide. There was no 
difference (F(1,15)=0.01) between H2O2 and ascorbylperoxide groups. 
The GSH values (Table 1) were higher (p < 0.01) in PN+GSSG group compared to the 
Sham group and PN groups. There was no difference (F(1,15)=0.5) between Sham and PN 
105
groups. Compared to the Control group (D), GSH levels were lower (p < 0.01) in groups 
that received H2O2 or ascorbylperoxide. There was no difference (F(1,15)=0.06) between 
H2O2 or ascorbylperoxide groups. Levels of GSSG (Table 1) did not statistically differ 
between groups (F(1,15) < 3.1).
The influence of the redox potential on MAT activity (Figure 5) was linear and significant 
(r2= 0.70, p<0.01) among the groups Sham, D, H2O2 and ascorbylperoxide (AscOOH) (-
0.080 U•mV-1•x – 14.3 U; U = nmol/min/mg prot). The relation was also significant (r2=
0.56, p<0.01) for the groups PN and PN+GSSG (-0.032 U•mV-1•x – 5.3 U). However, the 
slopes were statistically different (p<0.01, respectively (IC95): -0.080 (-0.105 to -0.056) and 
-0.032 (-0.050 to -0.014) U•mV-1). 
Discussion 
The main finding of the study is that, at least in newborn guinea pig, the mechanism of 
inhibition of the hepatic methionine adenosyltransferase (MAT) by parenteral nutrition 
(PN) is not explained solely by the classical and reversible oxidation of its thiol functions 
by the peroxides present in the nutritive solution. Therefore, the prevention of peroxides 
formation in PN or improving the redox potential value in liver by adding glutathione 
would not be enough to eliminate hepatic metabolic complications associated with this 
mode of nutrition.
The results confirm the induction of a lower activity of MAT (9) and a higher (more 
oxidized) redox potential of glutathione (9,21) in animals infused with PN or with 
peroxides that contaminate the nutritive solution. A classical way of inhibition of MAT is 
the reversible oxidation of its redox sensitive thiol functions by peroxides (Figure 1). It is 
through this mechanism that the H2O2 inhibits MAT, since the activity is recovered by 
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using DTT. The failure to obtain a rescue with DTT in tissues from PN group suggests that 
the inhibition is caused by a different way than oxidation of thiols by peroxide.
The metabolic importance of the activity of MAT led us to investigate a way to reverse its 
inhibition. Previously, we have added glutathione in PN to correct the low level of 
glutathione that is observed both in newborn animals (22) and in premature infants (23).
The rational was that 1) the hepatic transformation of methionine into cysteine by MAT is 
low in premature infants (24) and in individuals on PN (9), 2) the availability of cysteine 
being a limiting step for the glutathione synthesis, the liver produces and releases a lower 
quantity of glutathione in blood stream (25), 3) the presence of glutathione in PN allows to 
reach a higher plasma concentration of glutathione (17), 4) cellular J-
glutamyltranspeptidase uses GSH as well as GSSG present in plasma to enrich cells in 
cysteine for a de novo synthesis of GSH. Thus the addition of GSSG in PN has prevented 
the oxidation of redox potential in lung of animal on PN (17). With the same strategy, we 
wanted to improve the hepatic redox potential in order to improve the capacity of the liver 
to recycle the oxidized MAT (Figure 1). However, the results shown that even with an 
enhanced GSH level as well as a more reduced redox potential in animals fed with 
PN+GSSG, the activity of MAT remained inhibited. Yet, the value of the redox potential 
influences the MAT activity (figure 5). Nevertheless, there was a strong difference 
according if animals received or not PN. Seventy percent (r2=0.70) of the activity of MAT 
was explained by the redox potential in animals without PN. Data from all groups but PN 
(Sham, D, H2O2, ascorbylperoxide) were aligned on the same correlation, where the 
activity increases by one unit (nmol/min/mg prot) at each 12.5 mV reduction in the redox 
potential. Fifty-six percent (r2=0.56) of the activity of MAT was explained by the redox 
potential in animals on PN. However, here, the efficiency of redox potential on MAT is 
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lower; a reduction of 33 mV in redox potential is required to observe a one-unit increase in 
MAT activity. This 2.5 fold magnitude of change required in redox to obtain a same impact 
on MAT activity underlines that the inhibition observed with PN is from another kind in 
addition to oxidative. Of course, the relation between MAT and the redox potential is bi-
directional; the activity of MAT has also an influence on glutathione synthesis. 
Nevertheless, the difference between slopes remains and supports the presence of a 
different mechanism of inhibition between peroxides and PN. 
In liver, MAT activity is regulated by the oxidative state of their numerous thiols (10 per 
subunit (26)) that are present in active site (cysteinyl residue 121(11)) or are involved in 
oligomerization of the enzyme (11). MAT I is a homo tetramer whereas MAT III is a homo 
dimer (26). MAT I has a greater affinity for methionine (Km about 30 PM in rat liver (27))
than MAT III (11,27) (Km about 200 PM (27)). At physiological concentration of 
methionine (60 PM), the activity of MAT I is 10 fold greater than MAT III (26). The global 
activity of MAT as measured here is dependent of the proportion of MAT I and III. Their 
oligomerization involves several thiol functions (11,26). Sanchez-Perez GF et al (26)
reported that, in vitro, the oligomerization of MAT differs according to the presence of 
DTT (10 mM) or a mixture of GSH (10 mM) and GSSG (1 mM). DTT favours the 
formation of MAT III whereas GSH/GSSG favours a stable mixture of MAT I and III. 
Thus, with the glutathione system, we expect to have a greater global activity of MAT. The 
ratio GSH/GSSG is known to regulate the MAT activity (26,28). The calculated redox 
potential of glutathione used by Sanchez-Perez GF et al is -210 mV, a value close to that 
observed in our animals infused with H2O2, ascorbylperoxide or PN (Figure 3). The redox 
potential of the medium containing DTT is certainly more reduced (approximately -330 
mV). The figure 5 shows that the activity of MAT increased in function of reduction of 
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redox environment, whereas data from Sanchez-Perez GF et al (26) suggest the opposite, a 
greater activity (MAT I + III) in a more oxidized redox environment (-210 mV) compared 
to the lowest activity (mainly MAT I) in the most reduced redox environment (-330 mV) 
obtained with DTT.  This discrepancy suggests that the inhibition observed with PN, or 
with peroxides, does not occur at the level of oligomerization.  
The regulatory function of redox potential of glutathione on MAT activity observed in the 
present study supports the fact that the inhibitions are obtained following the oxidation of a 
thiol function, probably on the C121 at the active site as suggested by Pajares MA et al
(11). However, in animal infused with PN, the inhibition cannot be explained only by 
oxidation of this thiol function, since DTT was without effect. Other molecules must be 
involved. 4-Hydroxynonenal, from the lipid peroxidation of cellular membranes or from 
the lipid moiety of the PN, is a possible candidate. It is a well known that this aldehyde has 
a strong reactivity with several amino acids such as histidine, lysine and cysteine (29).
These kinds of involved reactions (Schiff-base formation or Michael addition) are 
irreversible and led to inactivation of several proteins (30).
Conclusion
The present report suggests that prevention of peroxide generation in PN and/or correction 
of the redox potential by adding glutathione in PN (17) are not sufficient, at least in 
newborn guinea pigs, to restore normal MAT activity. Further studies should be undertaken 
to identify all chemical players, in addition of peroxides, present in PN that influence the 
activity of the various isoforms of MAT. The knowledge of the molecules and pathways 
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implied is the first step in the prevention of deleterious effects of PN on hepatic 
metabolism.
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Table 1: Hepatic GSH and GSSG values as a function of treatments.
Sham PN PN +
GSSG
D H2O2 AscOOH
GSH 
(nmol/mg prot)
45r2 34r4 76r14* 79r18† 21r1 23r3
GSSG
(nmol/mg prot)
0.58r0.07 0.71r0.12 0.58r0.07 0.67r0.10 0.44r0.11 0.5r0.03
Sham: animals with closed catheter and enterally fed with chow; PN: animals exclusively on
parenteral nutrition; PN+GSSG: 10 PM GSSG added to PN; D: animals infused with a 
solution of dextrose; H2O2: D + 350 μM H2O2; AscOOH: D + 180 PM ascorbylperoxide. 
Two sets of statistical analyses were used according of the presence of methionine into 
their nutrition (Sham, PN, PN+GSSG). 1) There was no statistical difference in GSH 
between Sham and PN, both are different from PN+GSSG (*: p<0.01). 2) There was no 
statistical difference in GSH between H2O2 and AscOOH, both are different from D (†: 
p<0.01). The GSSG levels did not differ between groups. Mean r s.e.m., n= 4-7/group.
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Figure Legends 
Figure 1: Interrelation between MAT activity, peroxides and glutathione. 
The active form of MAT (MAT-SH) is responsible of the transformation of methionine in 
cysteine in order to sustain the synthesis of glutathione (GSH). In a context of PN, when 
MAT is inhibited (MAT-SOH) by peroxides (H2O2) generated into PN, a vicious cycle 
occurs. The low activity of MAT induces a low synthesis of GSH that is essential for the 
MAT recovery. By a compromised generation of the methyl donor S-adenosylmethionine 
(SAM), several metabolisms (proteins, DNA, phospholipids, neurotransmitters, etc.) are 
altered. SAH: S-adenosylhomocysteine. 
Figure 2: Stability of GSH and GSSG in PN.
PN contained 2% (w,v) amino acids, 8,7% (w,v) dextrose, 1% (v,v) multivitamin 
preparation and 1 U/mL heparin. The gray circle represents the initial concentration of 
GSH and GSSG added in PN. The concentration of total glutathione (GSH+GSSG, 
expressed in GSH equivalent) decreased in function of time. The drop was greater with 
GSH (open circle) than with GSSG (dark circle). Mean ± s.e.m. (some s.e.m. are smaller 
than the symbol), n= 3.
Figure 3: Impact of intravenous infusion of isolated peroxides or of the presence or not of 
glutathione in PN on the activity of methionine adenosyltransferase (MAT) and on the 
redox potential of glutathione in liver. 
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Sham: animals with closed catheter and enterally fed with chow; PN: animals exclusively on
parenteral nutrition; PN+GSSG: 10 PM GSSG added to PN; D: animals infused with a 
solution of dextrose; H2O2: D + 350 μM H2O2; AscOOH: D + 180 PM ascorbylperoxide. 
Two sets of statistical analyses were used according of the presence of methionine into 
their nutrition (Sham, PN, PN+GSSG). Panel A: The MAT activities were lower (p < 0.01) 
in groups PN and PN+GSSG compared to the Sham group and in groups H2O2 and 
AscOOH compared to the Control group (D). Panel B: The redox potential of glutathione 
was more reduced (lower) (p < 0.01) in PN+GSSG group than in Sham and PN and in D 
group compared to H2O2 and AscOOH groups. Mean r s.e.m., n= 4-9/group. **: p<0.01.
Figure 4: Impact of DTT on the activity of methionine adenosyltransferase (MAT).
Sham: animals with closed catheter and enterally fed with chow; PN: animals exclusively on 
parenteral nutrition; H2O2: animals infused with a solution of dextrose containing 350 μM 
H2O2. The presence of 1 mM DTT in the assay has improved (p<0.01) the activity of MAT 
only in the H2O2 group. Mean r s.e.m., n= 4-7/group. **: p<0.01.
Figure 5: Activity of hepatic methionine adenosyltransferase (MAT) in function of the 
redox potential of glutathione. 
The relation between MAT activity and the redox potential was statistically different 
(p<0.01) according to that the animals were infused with PN (rGSSG) or not. Without PN, 
the redox potential explained 70% of the variation in MAT activity (r2 = 0.70, p<0.01). 
With PN, the redox potential explained 56% of the variation in MAT activity (r2 = 0.56,
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p<0.01). However, with PN groups, the slope of the linear relationship was half (p<0.01) 
that observed with animals without PN. Open circles: Sham; open squares: D; x: H2O2; +:
AscOOH; gray diamonds: PN; gray triangles: PN+GSSG. 
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Key words: Premature newborn; bronchopulmonary dysplasia; ascorbylperoxide; 
apoptosis; hypoplasia; redox potential of glutathione.
Highlights
x Incidence of bronchopulmonary dysplasia (hypoplasia) is high in premature infants
x Ascorbylperoxide from parenteral nutrition (PN) induces loss of alveoli in animal
x Glutathione level is low in premature infants
x Adding glutathione in PN prevents apoptosis and loss of alveoli in newborn guinea pig
x Proposed mechanism:  detoxification of ascorbylperoxide by glutathione peroxidase
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Abstract 
Bronchopulmonary dysplasia, a main complication of prematurity, is characterized by 
an alveolar hypoplasia. Oxidative stress is suspected to be a trigger event in this 
population who has a low level of glutathione, a main endogenous antioxidant, and who 
receives high oxidative load, particularly ascorbylperoxide from their parenteral 
nutrition. Hypothesis: the addition of glutathione (GSSG) in parenteral nutrition 
improves detoxification of ascorbylperoxide by glutathione peroxidase and therefore 
prevents exaggerated apoptosis and loss of alveoli. 
Methods: Ascorbylperoxide is assessed as substrate for glutathione peroxidase in 
Michaelis-Menten kinetics. Three-days old guinea pig pups were divided in 6 groups to 
receive, through a catheter in jugular vein, the following solutions: 1) Sham (no 
infusion); 2) PN(-L): parenteral nutrition protected against light (low ascorbylperoxide); 
3) PN(+L): PN without photo-protection (high ascorbylperoxide); 4) 180 PM
ascorbylperoxide; 5) PN(+L) + 10 PM GSSG; 6) ascorbylperoxyde + 10 PM GSSG. 
After 4 days, lungs were sampled and prepared for histology and biochemical 
determinations. Data were analysed by ANOVA, p<0.05. 
Results: The Km of ascorbylperoxide for glutathione peroxidase was 126r6 PM and 
Vmax was 38.4r2.5 nmol/min/ U. The presence of GSSG in intravenous solution has 
prevented the high GSSG, oxidized redox potential of glutathione, activation of caspase-
3 (apoptosis marker) and loss of alveoli induced by PN(+L) or ascorbylperoxide.
Conclusion: A correction of the low glutathione levels observed in newborn animal on 
parenteral nutrition, protects lungs from toxic effect of ascorbylperoxide. Premature 
infants having a low level of glutathione, this finding is of high importance because it 
provides hope in a possible prevention of bronchopulmonary dysplasia.
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Introduction 
Bronchopulmonary dysplasia (BPD) is a main complication of prematurity. The exact 
aetiology of this chronic lung disease, characterized by alveolar hypoplasia, is unknown. 
Nonetheless there is a general consensus that oxidative stress is a triggering event. In 
this population, the two main oxidative sources are oxygen supplement because 
pulmonary immaturity and parenteral nutrition (PN) because gastrointestinal track 
immaturity. The link between oxygen supplement and development of BPD is well 
described [1]. In the last two decades, physicians were more careful with oxygen 
administration. Despite this caution in the use of supplemental oxygen, the incidence of 
BPD remains high [2].  
The other main source of oxidant molecules is PN. The interactions between electron 
donors such as vitamin C and dissolved oxygen in the intravenous solution generate 
peroxides [3, 4]. A typical PN administered to premature infants, containing 1% of 
multivitamin preparation generates between 300 and 400 PM peroxides [3,5], of which 
close to 80% are hydrogen peroxide [3]. The absence of adequate protection against 
ambient light accelerates the reaction. By using the light energy, the photo-excited 
riboflavin favours the transfer of electrons between ascorbate and oxygen. Full light 
protection reduces by half the generation of peroxides [5,6]. Since the photo-protection 
of PN has been reported to reduce the incidence of BPD [7,8], these peroxides are 
suspected to involve in BPD development. We have reproduced the effect of light 
exposure of PN on pulmonary alveolarization in newborn animal [9,10]. The 
administration on four days of PN that is devoid of light protection induces a loss of 
alveoli following an exaggerated apoptosis [10,11]. Recently we have shown that this 
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loss is not the effect of H2O2 but of a new molecule named ascorbylperoxide (2,3-
diketo-4-hydroxyperoxyl-5,6-dihydroxyhexanoic acid). This molecule is derived from 
peroxidation of dehydroascorbate by H2O2 [12,13]. 
Because an adequate photo-protection of PN, from pharmacy service, where the 
intravenous solution is compounded, until the bedside is practically impossible in 
clinical routine, we have investigated the possibility to improve the in vivo capacity to 
detoxify the ascorbylperoxide. The peroxide characteristic of this molecule suggested 
that it could be reduced by the action of glutathione peroxidase. Therefore, the first 
objective was to demonstrate the relationship between ascorbylperoxyde and glutathione 
peroxidase. The success of this approach suggested that the tissue concentration of 
glutathione (GSH) is important for this detoxification. 
At birth, the level of glutathione is dependent on gestational age [14]. In extreme 
premature newborns, the level of glutathione remains low for at least the first three 
weeks of life [14]. A lack of substrate for the de novo synthesis of glutathione explains 
this fact [15]. A low cellular availability of cysteine is a known limiting factor for 
glutathione synthesis [16]. This condition can be explained by the immaturity of capture 
of cysteine by cells [17] and by low capacity of liver to deliver glutathione in 
bloodstream. An important role of glutathione is to serve as pool of cysteine for cells 
[18]. J-Glutamyltranspeptidase on cellular membranes transfers the J-glutamyl moiety 
of glutathione to another amino acid in circulation thereby generating two dipeptides 
that are up-taken by the cells. Following dipeptidase action, amino acids are released for 
a new synthesis of glutathione. The activities of J -glutamyltranspeptidase and of 
synthetic enzymes are mature in preterm infants [19]. Glutathione present in
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bloodstream derives from the liver. This organ has high capacity to synthesize 
glutathione because it uses the transformation of methionine to generate cysteine. 
However, the first enzyme of this transformation, the methionine adenosyltransferase, is 
inhibited by peroxides from PN as shown in animal [20] and the last enzymatic step, the 
cystationase, is immature in premature infants [21,22]. We hypothesized that the 
addition of glutathione in PN bypasses the liver process of glutathione production, 
increases the cellular capacity to detoxify ascorbylperoxide and consequently prevents 
the loss of alveoli following infusion of PN. Therefore, the second aim of the study was 
to test in newborn animals, the impact of an addition of glutathione in PN on the 
pulmonary level of glutathione (GSH, GSSG and redox potential), apoptosis and 
alveolar development. 
Materials  
Guinea pigs were purchased from Charles River (St-Constant, Montréal, QC, Canada). 
Catheters were obtained from SAI Infusion Technologies (Lake Villa, IL, USA).
Intralipid20% was acquired from Fresenius Kabi Canada (Mississauga, ON, Canada). 
Multivitamin preparation (Multi-12/K1 paediatrics), amino acids (Primene) and dextrose 
were provided by Baxter (Toronto, ON, Canada). GSH, GSSG, L-ascorbic acid, 
riboflavin, catalase and glutathione peroxidase were bought from Sigma-Aldrich 
(Oakville, ON, Canada). Glutathione reductase was obtained from Roche Diagnostics 
(Indianapolis, IN, USA). L-2-oxo-thiazolidine 4-carboxilic acid (OTC) was acquired 
from Clintec (Deerfield, IL, USA). Hydrogen peroxide 30%, and ammonium acetate 
HPLC grade were purchased from Fisher (Fair Lawn, NJ, USA). Boric acid was 
obtained from J.T.Baker Chemical (Phillipsburg, NJ, USA). The Enzyme Immunoassay 
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Kit for the determination of 8-Isoprostane-F2D was provided by Cayman Chemical 
(Ann Arbor, MI, USA). Sep Pak C18 column were purchased from Water limited 
(Mississauga, On, Canada).
Methods 
In vitro study
Glutathione peroxidase reduces peroxides in their corresponding alcohol. Into the 
reaction, two electrons from GSH are transferred to the peroxide. The formed GSSG is 
recycled by glutathione reductase using NADPH as electron donor. In our assay, the loss 
of NADPH monitored at 340 nm is used to assess the activity of glutathione peroxidase. 
The enzymatic kinetic of glutathione peroxidase corresponds to the Michaelis-Menten 
model. Such kinetic using increasing concentrations of ascorbylperoxide allows the 
confirmation that ascorbylperoxide is detoxified by glutathione peroxidase. The reaction 
medium contained 50 mM GSH, 5 mM NADPH, 0 to 540 PM ascorbylperoxide, 0.25 U 
glutathione reductase in a buffer (250 mM TRIS, 0.1 mM EDTA-Na2) at pH 7.6. After 3 
minutes at 25ºC, the reaction was started with the addition of 0.1 U glutathione 
peroxidase (from human erythrocytes - according to Sigma - thus glutathione 
peroxidase-1). After one minute of reaction, the loss of NADPH was monitored at 340 
nm. The velocity of the reaction (v0) was obtained using the molar extinction coefficient 
of NADPH (6.22 mM-1•cm-1) and was expressed as Pmol NADP generated / minute / U 
glutathione peroxidase. 
In vivo study
A catheter was fixed in jugular vein of 36 guinea pigs aged of 3 days as previously 
described [10,20]. The studied intravenous solutions were infused continuously through 
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the catheter at a rate of 200 mL/kg/d. The solutions were changed daily. Animals were 
divided in six groups as followed: 
- Sham:    the catheter was closed by a node. Animals did not receive any intravenous 
solution. They were fed with regular food for guinea pig. 
- PN(-L):  animal were fed exclusively by intravenous solution containing 4 g/kg/d 
amino acids, 17.4 g/kg/d dextrose, 2 mL/kg/d multivitamin preparation, 3.2 
g/kg/d lipid emulsion and 1 U/mL heparin [20]. The solution was photo-
protected (-L) with opaque materials. We previously reported that this 
solution contains about 20 PM ascorbylperoxide [11].
- PN(+L): PN without photo-protection (about 75 feet-candle). We previously reported 
that this solution contains about 35 PM ascorbylperoxide [11]. 
- PN(+L)+GSSG: PN(+L) enriched with 10 PM GSSG. 
- Ascorbylperoxide: animals were fed exclusively by intravenous solution containing 
17.4 g/kg/d dextrose, 0.6 g/kg/d NaCl, 1 U/mL heparin and 180 μM
ascorbylperoxide. This concentration of ascorbylperoxide is about five time 
higher than the measured concentration in PN(+L) and served to test the 
robustness of the concentration of GSSG used. 
- Ascorbylperoxide+GSSG: ascorbylperoxide enriched with 10 PM GSSG.
GSSG was used rather than GSH because of its relative low reactivity with other 
components of parenteral nutrition. J-Glutamyltranspeptidase has similar affinity for 
GSSG and GSH [23]. The purpose of using a concentration of 10 PM was to reach the 
normal plasma concentration that range between 1 and 10 PM [24,25].
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Animals were kept on a 12h/12h light cycle. After four days of infusion, animals were 
sacrificed for collection of the lungs and of the urine in bladder. The left lung was filled 
with a solution of 10% formalin in PBS at a pressure of 10 cm water and was stored in a 
same solution for the histological preparation [10]. The right lung samples were 
removed, processed, aliquot and stored at -80ºC until biochemical determinations. The 
protocols were approved by the Institutional Committee for Good Practice with Animals 
in Research, in accordance with the Canadian Council of Animal Care guidelines.
Ascorbylperoxide generation
Because ascorbylperoxide does not commercially exist, it was generated in vitro, as 
previously described [11,12]. Briefly, ascorbylperoxide was generated by a solution 
containing 14.4 mM ascorbate + 3 mM H2O2 ȝ0ULERIODYLQS+7KHVROXWLRQZDV
incubated at room temperature with strong stirring under ambient light exposure (75 foot-
candle) for 48 hours. Thereafter, the solutions were treated 20 min with 100 U/mL catalase 
and filtered against a 30 kDa filter Amicon Ultra-15 (Millipore Corporation); FOX assay 
[26] has used to ensure the absence of H2O2.
Determinations
Ascorbylperoxide concentrations in the urine were determined by the Regional Centre of 
Mass Spectrometry of the Université de Montréal as followed. Centrifuged urine was 
directly injected on HPLC coupled to MS. Data were acquired on a 6224 TOF-LC/MS 
coupled to a 1260 Infinity HPLC system (Agilent Technologies, Santa Clara, USA). Mass 
Hunter 6.0 software (Agilent) was used to control the system and process the data. 
Separations were carried out on an Eclipse XDB-C18 analytical column (5 μm particles, 
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150 mm u 4.6 mm) maintained at 40oC. The eluents consisted of 10 mM Ammonium 
Acetate in water (eluent A) and acetonitrile (eluent B). The following gradient elution was 
applied at a flow rate of 500 μL/min: 0% B from 0 to 3 min; 0 to 80% B from 3 to 5 min; 
hold at 80% B for 1 min. Eluent B was then decreased from 80 to 0% from 6 to 6.2 min and 
held constant for up to 12 min to permit column equilibration. The injection volume was 3 
μL. Mass spectra were acquired from m/z 100-1500 in negative electrospray mode (VCap -
3500 V). Extracted ion chromatograms (±0.05 Da mass window) of deprotonated species 
were used for quantification. Because we have discovered [12,13] the existence of 
ascorbylperoxide, it is not commercially available. Therefore, L-2-oxo-thiazolidine 4-
carboxilic acid (OTC) was used as internal standard [27] and results were reported as OTC 
equivalent.  
Glutathione (GSH and GSSG) was measured by capillary electrophoresis, as previously 
described [11,20,27]. The redox potential was calculated (25ºC, pH 7) by using the Nernst 
equation with the assumption that the density of lung is 1 g/mL (needed to calculate the 
molar concentration of GSH and GSSG). Because the capillary electrophoresis detection 
threshold is relatively high for GSH and GSSG, respectively 1 and 0.25 PM, the method 
described by OW Griffith [28] was used to measure the low total glutathione (GSH+GSSG) 
concentration in plasma.
Caspase-3 was used as marker of apoptosis. The activated caspase-3 was defined by the 
proportion of cleaved caspase-3 on total caspase-3 (cleaved + non-cleaved) measured by 
Western blots as previously described [11]. 
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Alveolarization index was obtained by counting the number of intercepts between a 
standardized straight-line (1 mm) and histological structures. Each datum is the mean value 
from four different fields of the same lung (200X magnification) as described [10,11]. 
8-Isoprostane-F2D : Briefly, homogenized lung samples (1 in 9 volumes of buffer (50 mM 
Tris base, 0.1 mM EDTA, 200 PM indomethacin, pH 7.4)) were centrifuged at 10000 rpm 
during 10 minutes at room temperature. Sep Pak C18 columns were used to extract 
isoprostanes from the supernatants according to the method of Powell WS [29]. The levels 
of 8-Isoprostane-F2D were quantified by a commercial Enzyme Immunoassay Kit (Cayman 
Chemical, Ann Arbor, MI, USA) as previously reported [9].
Statistical analysis
Data are presented as mean ± S.E.M. and were compared by ANOVA with a level 
of significance set at p <0.05. The homoscedasticity was assessed by the Bartlett’s Chi 
squared test. The five orthogonal comparisons were 1) Sham versus PN(-L) to confirm the 
safety of the level of ascorbylperoxide that is present in the photo-protected PN as 
previously shown [11], 2) PN(+L) vs. PN(+L)+GSSG, 3) ascorbylperoxide vs. 
ascorbylperoxide+GSSG, 4) PN(+L)rGSSG vs. ascorbylperoxiderGSSG to confirm their 
similarity and 5) the complementary comparison [sham-PN(-L)] vs. [PN(+L) r GSSG –
ascorbylperoxide r GSSG].
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Results
The mean initial body weights of animals (107 r 2g) were similar between groups. Total 
glutathione concentration in plasma was higher in PN(+L)+GSSG than in PN(+L) group 
(0.5 r 0.2 vs. 14.2 r 0.4 PM, p<0.001). 
The Michaelis-Menten kinetics of glutathione peroxidase as shown in Figure 1A
supports the notion that ascorbylperoxide is detoxified by this enzyme.  From 
Lineweaver-Burk equation (Figure 1B), the Km was 126 +/- 6 PM (n = 3 different 
curves) and Vmax was 38.4+/-2.5 nmol/min/ unit of enzyme (n=3). 
In figures 2, 3 and 4, values from PN(-L) group were similar to those from Sham group 
(no statistic difference). The addition of GSSG in PN(+L) and in solution containing 180 
PM ascorbylperoxide did not change statistically the levels of GSH in lungs (p<0.05) 
(Figure 2A) but reduced the values of GSSG (p<0.01) (Figure 2B). These 
modifications resulted in prevention of oxidation of pulmonary redox potential by 
PN(+L) and ascorbylperoxide (p<0.05) (Figure 2C). Similarly, the addition of GSSG 
has prevented (p<0.05) the rise in apoptotic events as suggested by the elevated 
activation of caspase-3 under PN(+L) and ascorbylperoxide groups (Figure 3), and the 
loss (p<0.05) of alveoli number (Figure 4). The urinary concentration of 
ascorbylperoxide (Figure 5) was higher in PN(-L) than in Sham group (p<0.05) and 
higher in ascorbylperoxide than in PN(+L) groups (p<0.01). The levels of GSH and 
GSSG were lower (p<0.05) in animals infused with ascorbylperoxide in comparison to 
animals infused with PN(+L), independently of the presence of GSSG in the intravenous 
solutions. In contrast the redox potential, activation of caspase-3 and the alveoli number 
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measured in the ascorbylperoxide groups were similar to the values obtained with 
animals infused with PN(+L). The presence of GSSG in infused solutions had no effect 
on the urinary concentration of the ascorbylperoxide but this concentration was higher in 
animals infused with ascorbylperoxide. 
There was no significant difference in the pulmonary level of isoprostane-F2D between 
groups (Sham: 12r 2; PN(-L): 13r1; PN(+L): 15r2; PN(+L)+GSSG: 15r2; 
ascorbylperoxide: 14r1; ascorbylperoxide+GSSG: 14r1 pg/mg prot.)
Discussion
The main finding of the study is that the addition of GSSG in PN prevents activation of 
apoptosis and loss of alveoli induced by photo-oxidant molecules generated in PN such 
as ascorbylperoxide. This finding is of high importance because it provides hope for a 
possible prevention of BPD. 
The mechanism proposed by the results, could be a correction of redox potential of 
glutathione or an increase in GSH level in lung, even here the 20% increase did not 
reach the statistical significance. The absence of modification of the marker of lipid 
peroxidation, isoprostane-F2D, both in animals receiving an intravenous solution 
contaminated with peroxides than those receiving a PN enriched in GSSG, confirms the 
non-radical character of the mechanisms involved [9]. The first possibility is linked to 
the fact that oxidized redox potential is reported to be an inducer of apoptosis [30]. The 
values obtained in the present study are similar than those reported previously in 
comparable experiments [9,11]. However, the highest value of about -204 mV is not so 
high to induce apoptosis. The review from Shaffer et al [30] has associated this value to 
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the differentiation state of the cells rather than apoptosis. In developing organ, the redox 
potential must continually fluctuate to allow cells to pass from a state to another 
between proliferation (low redox value), differentiation and apoptosis (high redox 
value). In the present study, the redox values obtained in PN(+L) and ascorbylperoxide 
groups correspond more to differentiation state rather than apoptosis. The discrepancy 
between redox potential value and activation of apoptosis / loss of alveoli has been 
previously reported as two parallel effects caused by the ascorbylperoxide [11]. This 
previous study suggested that apoptosis is induced following activation of death 
receptors rather than by oxidation of redox potential. However, in the pathology of BPD, 
the observation of modification of redox potential is important. The histopathology of 
BPD is associated with a low alveolar development that can result from an exaggerated 
apoptosis as shown here, or (and) from reduction of pulmonary development that can be 
caused by a shift in redox potential to a value favouring differentiation. For instance, the 
association between high oxygen supplement and BPD [1,15] can be explained by the 
induction of a higher redox potential of glutathione, measured in blood, by the high 
oxygen concentration inspired by the infant [31,32]. We could extrapolate that high 
level of oxygen induces a slowing of alveolar development. Hence, the correction of 
pulmonary redox potential by addition of GSSG in PN could prevent the deleterious 
effects of oxygen supplement. In theory, increasing glutathione in plasma in order to 
improve availability of cysteine in tissue would help the infants to improve their 
antioxidant defenses based on GSH, especially if they are exposed to an oxygen 
supplementation. High oxygen stimulates the capacity of glutathione synthesis [33] as 
shown in premature infants [19]. Brown et al have previously reported [25] a protective 
impact of glutathione against the toxicity induced by oxygen. They have demonstrated 
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that infusion in preterm rabbits of 1 mM GSH (100 fold the concentration of GSSG used 
here) prevented the toxicity of 95% oxygen on lung compliance, edema and cell 
viability. By this experiment on 24 hours, the authors shown that the infusion of GSH 
had re-established the normal glutathione value in lungs (similar to the values presented 
here in figure 2), which was lower in animals exposed to 95% O2. Although these results 
support the notion that glutathione enrichment warns the toxicity of high levels of 
oxygen, they are not enough to prove that it may prevent deleterious effect of high 
oxygen supplementation on BPD development. Further studies are needed to assess the 
impact of adding GSSG in PN on the development of BPD in circumstance of the 
double exposure to PN and to oxygen support.  
The second possibility to explain the positive effect of GSSG addition in infused 
solutions is, according to the hypothesis, the fact that a better level of GSH favours a 
higher in vivo activity of glutathione peroxidase. Figure 1 shows that ascorbylperoxide is 
an excellent substrate for this enzyme. Results support the notion that a better 
availability of GSH allows a greater detoxification of ascorbylperoxide, and of other 
peroxides generated in PN. The low glutathione level in premature infants could explain 
their vulnerability to the ascorbylperoxide generated in the PN. 
The similarity of the protective effects of GSSG into PN (+L) and ascorbylperoxide
groups, suggests that the amount of used GSSG was sufficient to detoxify 
ascorbylperoxide to a concentration five times greater than that measured in the PN 
(+L). This high concentration of ascorbylperoxide could be observed in PN solutions 
containing higher concentration of multivitamin preparation [34]; photo-protection of 
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such solution could not sufficiently reduce the concentration of ascorbylperoxide in 
order to observe a lower incidence of BPD.    
As was previously demonstrated [11,27], the urinary concentrations of ascorbylperoxide 
reflect the amount of the infused molecules. These data confirm that animals from 
ascorbylperoxide groups have received a five time higher amount of ascorbylperoxide 
than animals infused with PN(+L). The similarity of results observed between PN(-L) 
and Sham groups could suggest that the photo-protection of PN is a possible procedure 
to reduce the ascorbylperoxyde to a safe level. However, in clinical situation, an 
adequate photo-protection is very hard to realize. Between its compounding in pharmacy 
service to the bedside, PN should never see the light, which is almost impossible in 
clinical routine. 
The rational use of GSSG rather than GSH was to improve the animal’s glutathione 
status while interfering as little as possible with the other compounds of the PN. We can 
expect that the glutathione will interact with the redox status of other antioxidants. 
These molecules are the ascorbate and, in a lesser extend, cysteine. By reducing the 
dissolved oxygen to generate H2O2 [4], ascorbate (AA) becomes dehydroascorbate 
(DHA). Because the standard reduction potential of the couple GSSG;2GSH (-0.23 V) is 
lower than those of DHA;AA (+0.06 V), GSH has the potential to reduce the DHA in 
ascorbate, perpetuating the generation of peroxides as oxygen remains available. Hence, 
all the GSH would become GSSG. If our choice was to use GSH rather that GSSG, the 
FRQFHQWUDWLRQ XVHG ZRXOG EH  ȝ0  WLPHV OHVV WKDQ DVFRUEDWH  P0 %\ LWV
relatively low concentration, GSH would be vulnerable. Its transformation in GSSG 
implies a radical intermediate (GS•). The high ratio of the other components of the PN
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on GSH (at least 4 orders of magnitude) increases the possibility that GS• reacts with 
other components of PN, with the final consequence of a loss of free glutathione. 
On the other hand, the high concentration of H2O2 generated in PN [3,9] may certainly 
interact with the thiol function of cysteine (CSH). This fact may explain the 90% loss of 
thiol functions in PN (exclusively from cysteine) in the 24 hours duration of PN 
(changed daily) [35]. The standard reduction potential of the couple CSSC;2CSH (CSSC 
being cystine) (-0.22 V) [36] is close but higher than that for GSSG;2GSH (-0.23V). 
Therefore, there remains a possibility that GSH may reduce CSSC into CSH, but not a 
reduction of GSSG by the CSH, even less at pH 5.5 of the PN solution. The most 
suitable possibility is a thiol exchange between GSSG and CSH to produce GSSC [36]. 
Despite these possible interactions, the objective was to improve glutathione level in 
plasma, and that has been reached.
Another conceivable side impact of the addition of GSSG into the PN is a modification 
of the redox status of cysteine/cystine or GSH/GSSG in plasma. The ratio cysteine (10-
25 PM) / cystine (50-150 PM) in plasma is in favour of cystine, at least in adults 
[37,38]. This ratio will definitely be more influenced by cysteine/cystine from the PN 
(initially 3.14 mM of cysteine before its oxidation into cystine) than by the infusion of 
10 PM GSSG. On the contrary, Brown et al [25] reported that the ratio of GSH / GSSG 
in plasma of preterm rabbits was in favor of the reduced form (GSH). Of course, by 
infusing, in continuous, GSSG directly in blood stream, we expect a modification of this 
ratio. Therefore, even with the favorable results obtained here with the addition of 
GSSG in PN, further studies are required to investigate the possible metabolic impact of 
this modification in newborn animals, and more in premature infants. The search for the
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minimal efficient dose of GSSG to add into PN solution may help to lowering this 
potential impact. 
Several differences exist between our animal model and extreme premature infants. 
However, the comparisons of some of the following factors suggest that our 
observations in animals could occur in human infants. For instance, 1) if GSH plays a 
key role, its level in premature newborn is low; 2) if a 4 days infusion of PN(+L) is 
sufficient to induce a loss of alveoli in animals, the median duration of PN is 20 (25th-
75th: 11-31; n=104) days (Sainte-Justine Hospital experience) in premies, 3) if the lung 
development of guinea pig newborn is mature at birth, the immaturity of lungs of 
premature infants can only worsen the situation. The toxicity associated to the 
ascorbylperoxide generated into the PN(+L) seems independent of the developmental 
stage of the lung. Indeed, the cell death (apoptosis) observed here in animals infused 
with PN(+L) has also been reported by others in isolated cells in culture. Nasef N et al
[4] showed the loss of viability of lung epithelial cells derived from preterm rats in 
presence of a solution of PN (primene + dextrose + multivitamins or ascorbate) devoid 
of photo-protection. They have associated this toxicity to the presence of 
hydroperoxides generated by ascorbate. Zaniolo K et al [39] had similar results (cell 
death) with human skin or lung fibroblasts as well as with mice embryonic fibroblasts 
cells exposed to a solution of parenteral multivitamin preparation devoid of light 
protection. For both studies, the cellular death was prevented by the photo-protection.
In conclusion, addition of GSSG in PN prevents the deleterious effect of 
ascorbylperoxide, generated in PN, on lung alveolarization of newborn animals born at 
term. Results suggest that the mechanism is by an improving of the GSH status in lung
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that favours detoxification of this peroxide. Even if caution is required before to 
extrapolate our finding to infants, the study brings hope in the fight against BPD.
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Legends for Figures
Figure 1:  Enzymatic kinetics of glutathione peroxidase in function of increasing 
concentration of ascorbylperoxide.
Panel A: Initial velocity of the reaction (v0) in function of increasing concentration of 
ascorbylperoxyde. The kinetic correspond to the Michaelis-Menten model. Data are 
expressed as mean r S.E.M., n=3. For some mean data, the S.E.M is smaller than the 
symbol. Panel B: Lineweaver-Burk representation of mean data from the panel A. The 
linear equation 1/ v0 = 3.246 (1/[S]) + 0.026 (1/v0) was highly significant (r2 = 0.998). 
From three different experiments, the apparent Km was 126 r 6 PM whereas the Vmax was 
38.4 r 2.5 Pmol NADP generated / minute / U glutathione peroxidase. 
Figure 2: GSH, GSSG and redox potential of glutathione in lungs.
Sham: animals with a closed catheter, animals were fed with regular food for guinea pig; 
PN(-L): animals fed exclusively with parenteral nutrition (PN) protected from light (-L); 
PN(+L): PN without photo-protection; AscOOH: animals infused with solution containing 
180 PM ascorbylperoxide (AscOOH); +GSSG: 10 PM GSSG were added to the 
intravenous solutions. Panel A: The GSH level was lower in the ascorbylperoxide group 
than in the PN(+L) group (p<0.05) independently of the presence of GSSG in the 
intravenous solutions. Panel B: the addition of GSSG in intravenous solutions has 
prevented (p<0.01) the increase of GSSG in lungs of animals infused with PN(+L) or 
ascorbylperoxide.  GSSG was higher (p<0.05) in PN(+L) than in ascorbylperoxide.  Panel 
C: The presence of GSSG in intravenous solutions have prevented (p<0.05) the oxidation 
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of redox potential of glutathione by PN(+L) and ascorbylperoxide. Mean r S.E.M., n=4-8
per group; *: p<0.05; **: p<0.01.
Figure 3: Activation of caspase-3 in lungs.
Sham: animals with a closed catheter, animals were fed with regular food for guinea pig; 
PN(-L): animals fed exclusively with parenteral nutrition (PN) protected from light (-L); 
TPN(+L): PN without photo-protection; AscOOH: animals infused with solution 
containing 180 PM ascorbylperoxide (AscOOH); +GSSG: 10 PM GSSG were added to the 
intravenous solutions. Panel A: The presence of GSSG in intravenous solutions have 
prevented (p<0.05) the activation of caspase-3 (marker of apoptosis) by PN(+L) and 
ascorbylperoxide. Panel B: Representative examples (n=2 per group) of Western blot 
obtained for the cleaved and non-cleaved caspase-3, relatively to tubulin. Mean r S.E.M., 
n=4-7 par group; *: p<0.05; **: p<0.01.
Figure 4: Alveolarization index.
Sham: animals with a closed catheter, animals were fed with regular food for guinea pig; 
PN(-L): animals fed exclusively with parenteral nutrition (PN) protected from light (-L); 
TPN(+L): PN without photo-protection; AscOOH: animals infused with solution 
containing 180 PM ascorbylperoxide (AscOOH); +GSSG: 10 PM GSSG were added to the 
intravenous solutions. Panel A: The presence of GSSG in intravenous solutions have 
prevented (p<0.05) the loss of alveoli by PN(+L) and ascorbylperoxide. Panels B-G: 
Representative examples of histological pictures of lungs of animals from PN(-L) group 
(B), Sham group (C), PN(+L) group (D), 180 ȝM ascorbylperoxide (E), PN(+L)+GSSG 
group (F) and 180 ȝM ascorbylperoxide+ GSSG group (G).  The alveolarization index is 
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based on the number of histological structures crossing the calibrated (1.5 mm) line. Mean 
r S.E.M., n=4-7 per group; *: p<0.05; **: p<0.01.
Figure 5: Urinary concentrations of ascorbylperoxide.
Sham: animals with a closed catheter, animals were fed with regular food for guinea pig;
PN(-L): animals fed exclusively with parenteral nutrition (PN) protected from light (-L); 
TPN(+L): PN without photo-protection; AscOOH: animals infused with solution 
containing 180 PM ascorbylperoxide (AscOOH); +GSSG: 10 PM GSSG were added to the 
intravenous solutions. The concentration of ascorbylperoxide was higher in the PN(-L) than 
in the sham group (p<0.05), higher in the ascorbylperoxide groups than in the PN(+L) 
groups (p<0.01). The presence of GSSG in intravenous solutions did not affect the urinary 
levels of ascorbylperoxide.  
Mean r S.E.M., n=4-6 per group; *: p<0.05; **: p<0.01.
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4. General discussion 
PN is a necessary form of nutrition for neonates with an impaired or immature 
gastrointestinal tract. However, laboratory animal studies and human investigations have 
shown that PN was associated with the development of BPD. Due to limited knowledge in 
the literature regarding PN and the incidence of BPD, no approach has yet been developed 
to address the mechanism with certainty. Nevertheless, through the various studies performed 
in our laboratory, we have discovered a by-product of vitamin C, an oxidant called 
ascorbylperoxide, which we think may be the main cause of BPD. The mechanisms 
whereby ascorbylperoxide, as a contaminant of PN, might lead to BPD are as yet unclear. 
An understanding thereof may help to optimize nutritional support of preterm infants and 
decrease the risk of BPD and subsequent chronic lung disease. Previous studies from our 
laboratory and other teams have shown that photoprotection of PN decreases the risk of 
BPD. This was shown by the complete protection of PN from light which in turn decreased 
the generation of peroxides contaminating PN, especially ascorbylperoxide and hydrogen 
peroxides. Recently, special attention paid to minimizing PN photodegradation by-products 
has shown a significant direct effect on preventing BPD, and it is becoming increasingly 
clear that light protection of PN can avoid specific metabolic complications in neonatal 
patients.
Unfortunately, it is difficult to obtain such photoprotection in the clinical setting. Because 
only a few minutes of light exposure is sufficient to generate significant amounts of oxidant 
molecules in PN solutions, photoprotection must be initiated from the time of PN 
preparation (without any exposure to light) all the way to the patient’s bedside where the 
bag and delivery tubes must be fully covered.
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Mohamed et al. have recently shown that early exposure to PN was associated with 
protracted oxidative stress until 36 weeks’ PMA, along with BPD. [167] This study showed 
that more than two weeks on PN was sufficient to observe an increasing in oxidized redox 
potential of glutathione at 36 weeks’ PMA. Oxidized redox potential can be considered a 
measure of oxidative stress. This threshold in duration of PN on redox potential was the 
same as that for the induction of BPD. [167] Thus our general hypothesis was that PN as 
administered in neonatal units is a major source of oxidative stress that contributes to the 
development of BPD.
The oxidative stress seems to derive mainly from the interaction between vitamin C and 
dissolved oxygen in the PN solution, which generates the oxidized form of vitamin C, 
DHA, as well as H2O2. The inorganic peroxides constitute approximately 80% of all 
peroxides generated in PN [170]. The reaction is accelerated by the photo-excited 
riboflavin that transfers energy from ambient light to the reaction. Photo-excited riboflavin 
also potentiates the reaction of the free radical species H2O2 with DHA, to form a new 
compound, ascorbylperoxide. [169, 172] We hypothesized that this oxidative stress, 
especially the modification of redox potential, might interfere with lung development. 
Lung maturation must pass through the cell cycle stages of proliferation, differentiation, 
and apoptosis in order to continue lung remodeling. Theses stages are dependent on the 
redox potential. The shift from a reduced state to an oxidized state induces proliferation, 
differentiation and apoptosis. During the proliferation phase, when the redox value is 
highly reduced, cells have a high metabolic rate leading to increased generation of ROS. 
These ROS shift the redox potential toward an oxidized state, inducing the differentiation 
phase; apoptosis occurs when the cell is in an even more oxidized state. [195] So we think 
that the peroxides contaminating the PN solution increase the redox potential to an oxidized 
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state, leading to apoptosis. Apoptosis decreases the number of the alveolar cells, which is 
the hallmark characteristic of BPD. 
In fact, PN solutions are contaminated with a number of molecules having the ability to 
disturb the redox status of the lung, such as ascorbylperoxide [119, 196] and H2O2. [170, 
197] Glutathione is considered a key element of antioxidant defenses and an important 
regulator of the redox system. All of these molecules, including AscOOH and H2O2, are 
detoxified by the glutathione system. On the other hand, glutathione levels are low in 
preterm infants, so these molecules can overcome the glutathione system, allowing the 
redox potential to shift toward an oxidized state. This fact is supported by studies in 
animals and premature infants. In animals, specifically in newborn guinea pigs, the infusion 
of PN without light protection for 4 days showed: 1) a decreased level of glutathione [198]; 
2) a more oxidized glutathione redox potential [199]; and 3) a lower alveolar count as 
compared to animals infused with a fully photo-protected solution. [199, 119] In premature 
infants (26 ± 1 weeks’ gestation), the blood glutathione redox potential measured on 
postnatal day 7 was correlated with the severity of BPD; a more oxidized status was 
measured in the most severe cases. [200] According to our hypothesis, peroxides generated 
in PN induce the development of BPD in preterm infants. The proposed mechanisms are 
oxidation of the redox potential of glutathione by AscOOH and/or H2O2; this oxidized state 
induces overstimulation of apoptotic mechanisms, followed by loss of alveolar tissue. We 
therefore evaluated the impact of AscOOH with and without H2O2 on the metabolism of 
glutathione. This was achieved by infusing newborn guinea pigs with solutions containing 
increasing concentrations of AscOOH with and without H2O2, and measuring lung 
concentrations of GSH and GSSG, redox potential, and level of apoptosis. The results were 
reported in the first article.
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AscOOH induced: 1) oxidation of the redox potential; 2) activation of caspase-3, which is a 
step of no return in apoptosis; and 3) a lower alveolarization index. The second part of the 
hypothesis was that contamination of PN with H2O2 exacerbates the oxidative stress and 
consequently influences the impact of ascorbylperoxide. Indeed, infusion of 350 μM H2O2
(without AscOOH) induced an increasing of the redox potential that reached a plateau. The 
mean redox value measured in animals infused with solutions containing H2O2 was similar 
to that observed in animals infused with solutions containing the two highest concentrations 
of AscOOH (without H2O2). This observation suggests that the redox potential might not be 
the main trigger of apoptosis. Indeed, although animals infused with H2O2 had the most 
oxidized redox potential, independently of the presence of AscOOH, the activation of 
caspase-3 induced by AscOOH was 15% lower in H2O2 groups. Nonetheless, the activation 
of caspase-3 induced by AscOOH in the presence of H2O2 remained sufficient to induce a 
decrease in alveolar number. The effect of AscOOH on the alveolarization index was 
similar to the values previously reported in studies investigating the effect of PN. [199]
The observations that the redox potential does not seem to play a key role in the activation 
of caspase-3 and that H2O2 reduces the activation of caspase-3 suggest that the impact of 
ascorbylperoxide on caspase-3 is through the death receptors. In the pathway from these 
receptors to apoptosis, caspase-8 is first activated and then caspase-3 is activated. The fact 
that caspase-8 is sensitive to inhibition by H2O2 [201] could explain the negative impact of 
H2O2 on activation of caspase-3 in our animal model. This pathway remains to be 
investigated. 
The main finding of this research is that AscOOH, a by-product of peroxidation of DHA 
generated in the solution of PN, is toxic to the lung in our animal model. Similarly, Zaniolo 
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K et al [202] reported that incubation of isolated cells in culture with the parenteral 
multivitamin Multi-12, as used here, induced cell death; photoprotection of the parenteral 
solution prevented this toxic effect. After a four-day infusion in animals, AscOOH induced 
a main feature of BPD, namely a lower alveoli number, independently of the presence of 
H2O2.
According to our hypothesis, higher levels of GSH favour higher in vivo activity of 
glutathione peroxidase. Our results showed that AscOOH was an excellent substrate for 
this enzyme. Results support the notion that greater availability of GSH allows for greater 
detoxification of AscOOH and other peroxides generated in PN. In parallel, Mohamed et al. 
has shown that preterm infants have a limited capacity for AscOOH detoxification, as 
shown by the accumulation of AscOOH in the first week following birth. A urinary 
AscOOH level on postnatal day 7 was shown in this study to be a good predictor of BPD 
severity in preterm infants less than 29 weeks of gestation [203]. 
Because GSH is the main contributor to the cellular redox environment and the main 
antioxidant for detoxification of peroxides via glutathione peroxidase, the low GSH level 
observed in premature infants could be a key factor in BPD development. Thus we believe 
that a possible strategy to prevent BPD development or reduce the severity of this disease 
may be the preservation or increase of intracellular concentrations of GSH. Our hypothesis 
is based on the fact that the low GSH levels observed in preterm infants are not caused by 
immaturity of the enzymatic process. GSH synthesis is very active, even in newborns of 26 
weeks’ gestation [154]. The low intracellular availability of cysteine limits glutathione 
synthesis [152]. The immaturity of the cellular cysteine transport system explains the 
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failure of intravenous enrichment of cysteine or N-acetylcysteine to improve GSH levels 
and prevent the development of BPD [204]. 
Gamma glutamyl transpeptidase plays an important role in supplying cells with needed 
cysteine for the synthesis of GSH [205]. This omnipresent enzyme transfers the J-glutamyl 
moiety of GSH present in plasma (from liver) onto a second amino acid, forming two 
dipeptides (glutamyl-amino acid and cysteinylglycine). These dipeptides are absorbed by 
the cell and hydrolysed into free amino acids. Free cysteine availability in the cell is a 
limiting factor for de novo synthesis of GSH [148]. 
The capabilities of J-glutamyl transpeptidase and other synthesizing enzymes are well 
developed in preterm infants [154]. GSH is present in the bloodstream and emanates from 
the liver. This organ has a high capacity for synthesizing GSH through the transformation 
of methionine to cysteine. However, the first enzyme of this transformation, MAT, is 
inhibited by peroxides from PN, as shown in animal models, and the last enzymatic step, 
cystathionase, is immature in premature infants. The inhibition of MAT by PN has been 
associated with low GSH levels in the blood [206], liver [206], and lung [207].
In order to prevent the development of BPD in premature infants, we have to reduce the 
oxidative stress or help newborns detoxify peroxides from PN. This can be done by 
preventing GSH loss or by increasing intracellular levels of GSH. On the other hand, 
decreasing or limiting peroxides that contaminate PN is critical but difficult to achieve. 
Thus we hypothesized that the addition of GSH to PN solutions, bypassing the liver for 
GSH production, should increase the cellular capacity to detoxify AscOOH and 
consequently prevent the loss of alveoli associated with PN. We chose to add GSSG rather 
GSH to PN. The rational for this choice was based on: 1) stability of the molecule in PN 
solution, as explained in the second article of the thesis and demonstrated in the third one; 
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and 2) similar affinity of J-glutamyl transpeptidase for both forms of glutathione [148, 
208]. The results were spectacular: by correcting the low plasma glutathione (from 0.5 PM
to 14 PM), we prevented the oxidation of the redox potential, the activation of caspase-3, 
and the loss of alveoli in animals on PN. This demonstration suggests that individuals with 
low glutathione such as premature infants, are susceptible to the toxicity of peroxides, 
especially AscOOH, that are infused with PN. In fact, administration of PN induces a 
pernicious cycle, because peroxides from PN also inhibit the generation of glutathione by 
the liver. We have reported that, at least in newborn guinea pigs, the mechanism of PN 
inhibition of hepatic MAT is not explained solely by the classical and reversible oxidation 
of its thiol functions by peroxides present in solution [206]. The prevention of peroxide 
formation in PN or improving the redox potential in the liver would therefore not be 
enough to eliminate metabolic complications associated with this mode of nutrition. Our 
interpretation of these results leads me to believe that the inhibition of MAT in animals 
infused with PN is caused not only by peroxides but also by other compounds such as 
aldehydes from the peroxidation of endogenous lipids in the parenteral lipid emulsion. Our 
results highlight the fact that the addition of GSSG is good for the lung, whereas the 
hepatic metabolism is still disrupted. We must therefore also work to reduce the generation 
of undesirable molecules in PN.
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5. Conclusion
PN as administered in neonatal units seems to be the major source of oxidative stress that 
contributes to the development of BPD. AscOOH generated in PN appears to be the active 
component leading to the loss of alveoli with apoptosis. Although AscOOH induces 
oxidation of the redox potential, the results of the present study suggest that it is a parallel 
phenomenon to the apoptosis. Indeed, the redox value obtained could be insufficiently 
oxidized to induce apoptosis. However, this change should not be taken lightly. The 
oxidation of the redox potential obtained with AscOOH or H2O2 could affect the balance 
between the proliferation and differentiation stages of the cell. A developing organ such as 
the lung in newborns must pass through different stages (cellular proliferation, 
differentiation and apoptosis) to promote its remodelling until final maturity. BPD may 
result from the perturbation of several of these cellular stages. Here, with our experimental 
model, we have explored the loss of alveoli, a feature of BPD, induced by the AscOOH
generated in PN solutions. Nevertheless, because the generation of AscOOH is dependent 
on light exposure, the present study explains the beneficial effect of photoprotection of PN 
solutions on chronic lung disease such as neonatal BPD. The results generated by this study 
add an important piece of information regarding the mechanisms by which PN as presently 
compounded may induce the development of BPD. 
GSH plays a vital role against ROS-induced injury under physiological and disease 
conditions. The concentrations of GSH and GSSG are very important in the maintenance of 
the redox potential, pivotal to cell survival and development. Premature infants exposed to 
high concentrations of oxygen in the first few weeks after birth experience an additional 
oxidative burden on the GSH system.
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In animals born at term, the addition of GSSG in PN prevents the deleterious effect on 
lung alveolarization of the AscOOH generated in PN solutions. Results suggest that the 
mechanism may involve an improvement of the GSH status in the lung, favouring 
peroxide detoxification. Even if caution is required before implementing these findings 
in infants because of the unknown physiological impact of increasing GSH 
concentrations, the study brings hope in the fight against BPD. 
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6. Limitations 
PN is a mode of nutrition frequently used in neonates born before 30 weeks of gestation. 
The investigation of the impact of PN in this population is difficult because of the lack of 
the biological samples from premature infants and the absence of a control group 
(premature infants not given PN). The use of newborn animals born at term enabled us to 
study the impact of PN during the neonatal period, independent of prematurity. Therefore, 
caution is needed in the extrapolation of data to human premature newborns. Further, the 
physiological impact of increasing GSH concentrations is unknown. Further research in 
long- and short-term effects is necessary before introducing these strategies in the clinical 
setting.
Gender is an important determinant in the incidence of BPD, which is higher in boys than 
girls [143]. An animal model was used to demonstrate the links between AscOOH and 
alveolar hypoplasia and to test the safety of PN solutions. The achievement of these 
objectives could be reached using animals of the same gender, all males. However, because 
the animals used in our experiments were all males, results of my work do not provide 
additional information to explain the gender factor. In my opinion, it would be interesting 
to repeat the experiments with female animals to isolate the effect of gender. With the 
hypothesis that low levels of glutathione are the main cause of the BPD, and glutathione 
levels are reportedly lower in male premature infants [143], it makes sense that males have 
a higher prevalence of BPD. If this hypothesis were proven true, we would obtain the same 
results with females. On the other hand, if a gender difference remains independently of 
glutathione, a new avenue of research could be undertaken to explain the impact of gender 
on health fragility in this age group. 
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Oxygen supplementation and PN, the main sources of oxidative stress, are both frequently 
administered to preterm infants. In our experiments, the animals were exposed only to the 
PN, without hyperoxia. This is another limitation in the extrapolation of findings to 
premature infants. Moreover, we expect that the effects of the two sources of oxidants are 
additive. Further studies are needed to investigate the combination of the two. 
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7. Perspectives and future work
Our results demonstrate that AscOOH generated in PN appears to be the active component 
leading to apoptosis and alveolar loss [207]. However, AscOOH activation of apoptosis 
through death receptors remains to be validated. One possible mechanism would be the 
oxidation of cysteine in death receptor proteins (similar to the way that AscOOH inhibits 
MAT), i.e. through oxidation of an active thiol receiver. Further studies are needed to 
investigate the impact of AscOOH on the death receptor activation.
In our research, we infused 10 μM of GSSS and obtained 14 PM glutathione in the plasma. 
The physiological and maximal value reported as being normal is 10 PM. It will be 
important to investigate different concentrations of GSH to add to PN solutions, to 
determine the minimal and effective plasma level of GSH that can prevent the deleterious 
effects of peroxides in PN. This value would be the concentration to expect during a 
clinical trial. Moreover, before introducing this practice in a clinical setting, further 
research is necessary to investigate possible long-term consequences of early-life 
modification of the glutathione system. 
Our results demonstrate that the addition of GSSG to PN prevents the activation of 
apoptosis and the loss of alveoli induced by photo-oxidant molecules generated in PN, such 
as ascorbylperoxide [207]. An equally important question is whether the addition of GSSG 
will provide protection during oxygen supplementation or hyperoxia. In fact, increasing 
GSH in plasma to improve the availability of cysteine in tissues could help infants improve 
their GSH-related antioxidant defenses, especially if they are exposed to oxygen 
supplementation. High oxygen stimulates glutathione synthesis [209], as shown in 
premature infants [154]. Brown et al have previously reported [210] the protective effect of
GSH against the toxicity induced by oxygen. They demonstrated that infusion of 1 mM 
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GSH in preterm rabbits (100-fold concentration of the GSSG used in our protocol) 
prevented the toxicity of 95% oxygen on lung compliance, edema, and cell viability. With 
this experiment, which spanned a period of 24 hours, the authors showed that the infusion 
of GSH had re-established normal glutathione levels in the lungs (similar to our values), 
which was lower in animals exposed to 95% O2. Although these results support the notion 
that glutathione enrichment wards off the toxicity of high levels of oxygen, they are not 
enough to prove that it may prevent the deleterious effect of high oxygen supplementation 
on lung development, namely BPD. Further studies are needed to assess the impact of 
adding GSSG to PN to prevent the development of BPD in infants exposed to a 
combination of both PN and oxygen support.
MAT is at the crossroads of several metabolic pathways for example DNA methylation 
further studies needed to examine the impact of PN on the DNA methylation.
Finally it will be urgent to apply this new nutritive solution for the neonates in order to 
decrease the incidence of the complications related to oxidative stress for this population by 
increase the production of GSH.
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